BIO RAD LABORATORIES INC, 10-Q, 1999-11-12

BIO RAD LABORATORIES INC
10-Q, 1999-11-12
LABORATORY ANALYTICAL INSTRUMENTS

Previous: BESSEMER TRUST CO, 13F-NT, 1999-11-12

Next: AXIA INC, 10-Q, 1999-11-12

<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 1999.

__ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________.

Commission file number 1-7928

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Delaware 94-1381833
(State or other jurisdiction (I.R.S. Employer
of incorporation) Identification No.)

1000 Alfred Nobel Drive, Hercules, California 94547
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (510) 724-7000

Indicate by check whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No ___

Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date--

<TABLE>
<CAPTION>
Shares Outstanding
Title of each Class at October 31, 1999
<S> <C>
Class A Common Stock,
Par Value $1.00 per share 9,977,762

Class B Common Stock,
Par Value $1.00 per share 2,484,816

</TABLE>

<PAGE>
PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

BIO-RAD LABORATORIES, INC.

Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
September 30, September 30,
1999 1998 1999 1998

<S> <C> <C> <C> <C>
NET SALES . . . . . . . . . . . . . . . . . . $113,527 $ 98,982 $355,059 $323,054

Cost of goods sold . . . . . . . . . . . . . 51,899 45,405 158,008 146,544

GROSS PROFIT . . . . . . . . . . . . . . . . 61,628 53,577 197,051 176,510

Selling, general and administrative expense . 43,618 41,042 128,440 123,610

Product research and development expense . . 10,999 10,243 32,449 30,784

INCOME FROM OPERATIONS . . . . . . . . . . . 7,011 2,292 36,162 22,116

Interest expense . . . . . . . . . . . . . . (755) (941) (2,458) (2,817)

Investment income, net. . . . . . . . . . . . 516 1,955 939 7,585

Other, net . . . . . . . . . . . . . . . . . (815) (577) (2,520) (1,722)

INCOME BEFORE TAXES . . . . . . . . . . . . . 5,957 2,729 32,123 25,162

Provision for income taxes . . . . . . . . . 1,704 791 9,187 7,297

NET INCOME . . . . . . . . . . . . . . . . . $ 4,253 $ 1,938 $ 22,936 $ 17,865
======== ======== ======== ========

Basic earnings per share:
Net income . . . . . . . . . . . . . . . . $0.35 $0.16 $1.89 $1.46
======== ======== ======== ========
Weighted average common shares . . . . . . 12,111 12,302 12,105 12,259
======== ======== ======== ========
Diluted earnings per share:
Net income . . . . . . . . . . . . . . . . $0.35 $0.16 $1.89 $1.44
======== ======== ======== ========

Weighted average common shares . . . . . . 12,195 12,394 12,164 12,381
======== ======== ======== ========
</TABLE>

The accompanying notes are an integral part of these statements.

1
<PAGE>

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share data)

<TABLE>
<CAPTION>
September 30, December 31,
1999 1998
(Unaudited)
<S> <C> <C>
ASSETS:
Cash and cash equivalents . . . . . . . . . . . . . . . . $ 11,826 $ 10,081
Accounts receivable . . . . . . . . . . . . . . . . . . . 105,213 106,010
Inventories . . . . . . . . . . . . . . . . . . . . . . . 96,385 92,411
Prepaid expenses, taxes and other current assets. . . . . 26,927 26,887
Total current assets . . . . . . . . . . . . . . . . . 240,351 235,389

Net property, plant and equipment . . . . . . . . . . . . 85,005 82,130
Marketable securities . . . . . . . . . . . . . . . . . . 1,539 6,174
Other assets . . . . . . . . . . . . . . . . . . . . . . 49,236 43,606
Total assets . . . . . . . . . . . . . . . . . . . . $376,131 $367,299
======== ========

LIABILITIES AND STOCKHOLDERS' EQUITY:
Notes payable and current maturities of long-term debt. . $ 9,747 $ 9,393
Accounts payable . . . . . . . . . . . . . . . . . . . . 22,348 26,706
Accrued payroll and employee benefits . . . . . . . . . . 30,379 27,351
Sales, income and other taxes payable . . . . . . . . . . 2,059 6,396
Other current liabilities . . . . . . . . . . . . . . . . 27,541 27,398

Total current liabilities . . . . . . . . . . . . . . 92,074 97,244
Long-term debt, net of current maturities . . . . . . . . 35,367 42,339
Deferred tax liabilities . . . . . . . . . . . . . . . . 14,494 13,382

Total liabilities . . . . . . . . . . . . . . . . . . 141,935 152,965
STOCKHOLDERS' EQUITY:
Preferred stock, $1.00 par value, 2,300,000 shares
authorized; none outstanding . . . . . . . . . . . . . -- --
Class A common stock, $1.00 par value, 15,000,000 shares
authorized; outstanding - 9,977,762 at September 30, 1999
and 9,973,679 at December 31, 1998 . . . . . . . . . . 9,978 9,974
Class B common stock, $1.00 par value, 6,000,000 shares
authorized; outstanding - 2,484,816 at September 30, 1999
and 2,452,899 at December 31, 1998 . . . . . . . . . . 2,485 2,453
Additional paid-in capital . . . . . . . . . . . . . . . 18,779 18,523
Class A treasury stock, 348,080 shares at September 30, 1999
and 306,368 shares at December 31, 1998 at cost . . . . (7,670) (7,047)
Retained earnings . . . . . . . . . . . . . . . . . . . . 212,201 189,838
Accumulated other comprehensive income:
Currency translation . . . . . . . . . . . . . . . . . (1,540) 92
Net unrealized holding gain (loss)on marketable
securities . . . . . . . . . . . . . . . . . . . . . (37) 501

Total stockholders' equity . . . . . . . . . . . . . . 234,196 214,334
Total liabilities and stockholders' equity . . . . $376,131 $367,299
======== ========
</TABLE>

The accompanying notes are an integral part of these statements.

2
<PAGE>

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

<TABLE>
<CAPTION>
Nine Months Ended
September 30,
1999 1998
<S> <C> <C>
Cash flows from operating activities:
Cash received from customers . . . . . . . . . . . . $350,345 $323,661
Cash paid to suppliers and employees . . . . . . . . (311,890) (298,711)
Interest paid. . . . . . . . . . . . . . . . . . . . (2,508) (2,680)
Income tax payments. . . . . . . . . . . . . . . . . (12,987) (6,580)
Miscellaneous receipts (payments). . . . . . . . . . (47) 170
Net cash provided by operating activities. . . . . . 22,913 15,860

Cash flows from investing activities:
Capital expenditures, net. . . . . . . . . . . . . . (17,809) (14,415)
Purchases of marketable securities and investments . (2,148) (17,922)
Sales of marketable securities and investments . . . 6,230 13,791
Foreign currency hedges, net . . . . . . . . . . . . 1,585 20
Net cash used in investing activities. . . . . . . . (12,142) (18,526)

Cash flows from financing activities:
Net borrowings under line-of-credit arrangements . . (143) (400)
Long-term borrowings . . . . . . . . . . . . . . . . 94,225 108,910
Payments on long-term debt . . . . . . . . . . . . . (103,032) (109,345)
Proceeds from issuance of common stock . . . . . . . 292 58
Treasury stock activity, net . . . . . . . . . . . . (1,196) 1,156

Net cash provided by (used in) financing activities. (9,854) 379
Effect of exchange rate changes on cash . . . . . . . . . 828 (221)

Net increase (decrease) in cash and cash equivalents. . . 1,745 (2,508)
Cash and cash equivalents at beginning of period. . . . . 10,081 10,843

Cash and cash equivalents at end of period. . . . . . . . $l1,826 $ 8,335
======= =======
Reconciliation of net income to net cash provided
by operating activities:
Net income . . . . . . . . . . . . . . . . . . . . . . $ 22,936 $ 17,865
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization. . . . . . . . . . . 16,589 15,276
Foreign currency hedge transactions, net . . . . . (1,585) (20)
Gains on disposition of marketable securities. . . (870) (7,518)
(Increase) decrease in accounts receivable . . . . (2,268) 1,622
Increase in inventories . . . . . . . . . . . . . (4,800) (5,451)
Increase in other current assets . . . . . . . . . (733) (203)
Increase (decrease) in accounts payable and other
current liabilities. . . . . . . . . . . . . . . 1,126 (6,978)
Increase (decrease) in income taxes payable. . . . (5,232) 1,054
Other. . . . . . . . . . . . . . . . . . . . . . . (2,250) 213

Net cash provided by operating activities . . . . . . . . $ 22,913 $ 15,860
======= =======
</TABLE>
The accompanying notes are an integral part of these statements.

3
<PAGE>

BIO-RAD LABORATORIES, INC.

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial
statements of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the
"Company"), reflect all adjustments which are, in the opinion of
management, necessary to a fair statement of the results of the
interim periods presented. All such adjustments are of a normal
recurring nature. The condensed consolidated financial
statements should be read in conjunction with the notes to
consolidated financial statements contained in the Company's
Annual Report for the year ended December 31, 1998 (the Company's
1998 Annual Report). Certain amounts in the financial statements
of the prior year have been reclassified to be consistent with
the 1999 presentation.

2. INVENTORIES

The principal components of inventories are as follows:

September 30, December 31,
1999 1998
(in thousands)
<S> <C> <C>
Raw materials $ 26,168 $ 26,038
Work in process 19,404 21,614
Finished goods 50,813 44,759

$ 96,385 $ 92,411
======== ========
</TABLE>

3. PROPERTY, PLANT AND EQUIPMENT

The principal components of property, plant and equipment are as
follows:

<TABLE>
<CAPTION>
September 30, December 31,
1999 1998
(in thousands)
<S> <C> <C>
Land and improvements $ 8,057 $ 8,057
Buildings and leasehold
improvements 58,078 56,280
Equipment 138,873 133,838
205,008 198,175
Accumulated depreciation (120,003) (116,045)

Net property, plant and equipment $ 85,005 $ 82,130
======== ========

</TABLE>

<PAGE>

4. LONG TERM DEBT

The Company entered into a $200 million credit facility
(consisting of a $100 million term loan and a $100 million
revolving credit line) on September 30, 1999, replacing the $100
million credit agreement previously in place. The new facility
provides for borrowings on a secured basis through September 30,
2004. Interest is based upon the Eurocurrency rate, the Federal
Funds Effective rate or Bank One's base rate.

The Company also entered into a $100 million Senior Subordinated
Credit Agreement on September 30, 1999. This agreement has a one
year term and provides for an automatic rollover for an
additional term expiring September 30, 2005. The agreement
requires warrants to be placed in escrow equal to 10% of the
Company's fully diluted stock. The lenders are entitled to
receive these warrants in 25% quarterly increments beginning
April 1, 2000. The warrants entitle the holder to purchase the
Company's stock at 10% over the September 30, 1999 closing stock
price. The warrants expire September 30, 2009. Interest is
based upon LIBOR plus 6.0% for the first 180 days of the
agreement. The incremental rate increases 0.5% every quarter
thereafter to a maximum of 18.0%.

5. EARNINGS PER SHARE

Weighted average shares used for diluted earnings per share
include the dilutive effect of outstanding stock options of
84,000 and 92,000 shares, for the quarters ended September 30,
1999 and 1998, respectively.

Weighted average shares used for diluted earnings per share
include the dilutive effect of outstanding stock options of
59,000 and 122,000 shares, for the year-to-date periods ended
September 30, 1999 and 1998, respectively.

Options to purchase 262,000 and 140,000 shares of common stock
were outstanding during 1999 and 1998, respectively, but were
excluded from the computation of diluted earnings per share
because the exercise price of the options was greater than the
average market price of the common shares. The options were
still outstanding at September 30, 1999.

<PAGE>

6. COMPREHENSIVE INCOME

The components of the Company's total comprehensive income were:

Three Months Ended Nine Months Ended
September 30, September 30,
1999 1998 1999 1998
(in thousands)
<S> <C> <C> <C> <C>
Net income $ 4,253 $ 1,938 $22,936 $17,865
Currency translation adjustments 1,670 1,828 (1,632) 851
Net unrealized holding gains (losses) (404) (739) 82 696
Reclassification adjustments for
gains included in net income (367) (1,337) (620) (5,337)

Total comprehensive income $ 5,152 $ 1,690 $20,766 $14,075

</TABLE>

7. SEGMENT INFORMATION

Information regarding industry segments for the three months
ended September 30, 1999 and 1998 is as follows (in thousands):

<TABLE>
<CAPTION>
Life Clinical Analytical
Science Diagnostics Instruments
<S> <C> <C> <C> <C>
Segment net sales 1999 $53,416 $45,478 $15,002
1998 48,040 40,049 12,163

Segment profit (loss) 1999 $ 1,976 $ 5,091 $ 180
1998 1,124 3,988 (2,802)

</TABLE>

Information regarding industry segments for the nine months ended
September 30, 1999 and 1998 is as follows (in thousands):

Life Clinical Analytical
Science Diagnostics Instruments
<S> <C> <C> <C> <C>
Segment net sales 1999 $169,477 $138,111 $49,116
1998 151,821 126,228 48,121

Segment profit (loss) 1999 $ 13,708 $20,772 $ 942
1998 9,366 14,565 (3,424)

</TABLE>

Inter-segment sales are primarily between Life Science and Clinical
Diagnostics and are priced to give Life Science a representative gross
margin. The following reconciles total segment profit to consolidated
income before taxes:

Three Months Ended Nine Months Ended
September 30, September 30,
1999 1998 1999 1998
(in thousands)
<S> <C> <C> <C> <C>
Total segment profit $7,247 $2,313 $35,422 $20,507

Gross profit on inter-segment sales (176) (671) (813) (1,575)
Net corporate operating, interest
and other expense not allocated
to segments (1,630) (868) (3,425) (1,355)
Investment income, net 516 1,955 939 7,585

Consolidated income before taxes $5,957 $2,729 $32,123 $25,162
====== ======= ======= =======
</TABLE>

<PAGE>

8. SUBSEQUENT EVENT

On October 1, 1999, Bio-Rad acquired Pasteur Sanofi Diagnostics S.A.,
a French corporation ("PSD"), from its shareholders, Sanofi-Synthelabo
S.A. and Institut Pasteur. Bio-Rad acquired 100% of the capital stock
of PSD (and certain ancillary assets and assumed liabilities related
to PSD) for a purchase price, subject to post-closing adjustments, not
to exceed $210 million. The cash purchase price was financed through
a $200 million credit facility and a $100 million Senior Subordinated
Credit Agreement (see Note 4).

The acquisition of PSD and the related financing were recorded as of
October 1, 1999, the effective date of the transaction.

7
<PAGE>

ITEM 2. Management's Discussion and Analysis of Results of
Operations and Financial Condition.

This discussion should be read in conjunction with the
information contained both in this report and in the Company's
Consolidated Financial Statements for the year ended December 31,
1998. Pro-forma information regarding the acquisition of Pasteur
Sanofi Diagnostics S.A.("PSD") is included in the Company's Form
8-K dated October 1, 1999.

The following table shows operating income and expense items as a
percentage of net sales:

Three Months Ended Nine Months Ended Year Ended
September 30, September 30, December 31,
1999 1998 1999 1998 1998
<S> <C> <C> <C> <C> <C>
Net sales 100.0 100.0 100.0 100.0 100.0
Cost of goods sold 45.7 45.9 44.5 45.4 45.8
Gross profit 54.3 54.1 55.5 54.6 54.2

Selling, general and
administrative 38.4 41.5 36.2 38.3 37.8

Product research and
development 9.7 10.3 9.1 9.5 9.4

Income from operations 6.2 2.3 10.2 6.8 7.0
===== ===== ===== ===== =====
Net Income 3.7 2.0 6.5 5.5 5.5
===== ===== ===== ===== =====

</TABLE>

Forward Looking Statements

Other than statements of historical fact, statements made in this
report include forward looking statements, such as statements
with respect to the Company's future financial performance,
operating results, plans and objectives. Actual results may
differ materially from those currently anticipated depending on a
variety of risk factors including the successful integration of
PSD, increased competition, technological development, access to
necessary intellectual property, the ability to achieve
management objectives, government regulation, the continued
performance of business partners (particularly in relation to the
Year 2000 issue), and the monetary policies of various countries.

8
<PAGE>

Three Months Ended September 30, 1999 Compared to
Three Months Ended September 30, 1998

Corporate Results - Sales, Margins and Expenses

Net sales (sales) in the third quarter of 1999 reached $113.5
million compared to $99.0 million in the third quarter of 1998.
Sales increased 11.2% in Life Science, 13.6% in Clinical
Diagnostics, and 23.3% in Analytical Instruments when compared to
the third quarter of 1998. The growth in Life Science is
attributed to a broad line of core products, especially molecular
biology devices, imaging products and process chromatography.
Clinical Diagnostics experienced growth in its quality control
product lines and its diabetes line. The increase in Analytical
Instruments is attributed to the Company's semiconductor test and
manufacturing instruments, which were adversely impacted during
an industry slowdown for most of the second half of 1998.

Consolidated gross margins were 54.3% for the third quarter of
1999 compared to 54.1% for the third quarter of 1998 and 54.2%
for all of 1998. Gross margins were virtually unchanged in Life
Science, rose significantly in Analytical Instruments and
declined in Diagnostics. The improvements in Analytical
Instruments gross margin are attributed to increased sales volume
absorbing manufacturing overhead costs, and a stronger Japanese
currency improving the average US dollar sales price received.
Clinical Diagnostics margins were impacted by rising costs for
purchased equipment bought in a foreign currency and increases
in the placement of reagent rental equipment, as this segment's
"next generation" diabetes testing equipment replaces instruments
previously fully depreciated.

Selling, general and administrative expense (SG&A) decreased to
38.4% of sales in the third quarter of 1999 from 41.5% of sales
in the comparable period of 1998. Both Analytical Instruments
and Clinical Diagnostics had no increase in SG&A spending in the
third quarter of 1999 when compared to 1998. Life Science
increased SG&A spending but at a rate much slower than sales
growth. The long-term goal for management remains a consistent
gradual reduction in SG&A spending as a percent of sales.

Product research and development expense (R&D) increased 7.3% in
absolute dollars from the third quarter of 1998, but decreased
overall as a percentage of sales. Compared to the third quarter
of 1998, both Life Science and Clinical Diagnostics increased R&D
spending. Analytical Instruments reduced its R&D spending.

<PAGE>

Corporate Results - Non-Operating Items

Interest expense has declined consistent with lower average
borrowings when compared to the third quarter of 1998.
Borrowings will increase due to the purchase of PSD.
Accordingly, interest expense will also increase significantly.
Investment income in both years includes gains on sales of
marketable securities. The third quarter of 1999 includes an
additional reduction in the Company's marketable securities
portfolio to reduce debt further prior to entering into the new
credit facilities necessitated by the acquisition of PSD. Net
other income and expense in both years includes net goodwill
amortization and non-operating legal costs.

The Company's effective tax rate was 29% for the third quarter of
both 1999 and 1998. The tax rate for both years reflects the
utilization of loss carryforwards, foreign sales corporation
benefits and foreign tax credits. These benefits are not
expected to continue indefinitely and, subject to completion of
the PSD acquisition, will change. A determination of the impact
to the Company's effective tax rate from the pending acquisition
has not been completed; however, the rate may rise as limitations
may be imposed on the deductibility of some level of interest
expense and the amortization of certain intangibles.

Nine Months Ended September 30, 1999 Compared to
Nine Months Ended September 30, 1998

Corporate Results - Sales Margins and Expenses

Sales for the nine month period ended September 30, 1999 were
$355.1 million compared to $323.1 million in the comparable
period of 1998, an increase of 9.9%. For the first nine months
of 1999, the effect from a slightly weakened U.S. dollar added
$1.7 million to sales, accounting for only 0.5% of the sales
growth when compared to sales based upon the 1998 exchange rates.
Sales have increased 11.6% for Life Science, 9.4% for Clinical
Diagnostics, and 2.1% for Analytical Instruments. Life Science
sales increased across a broad line of core products, especially
its imaging products. Clinical Diagnostics sales continue to
grow for its quality control and diabetes product lines. The
Company's Analytical Instruments segment remains flat with the
prior year as the first half of 1999 saw a decline that was
offset by third quarter increases.

Consolidated gross margins were 55.5% for the first nine months
of 1999 compared to 54.6% for the first nine months of 1998 and
54.2% for all of 1998. Life Science margins improved slightly on
better than planned sales. Clinical Diagnostics margins
increased 1% due to a change in the product mix towards higher
margin products. Analytical Instruments margins improved on
higher sales and continued manufacturing overhead reductions.

SG&A decreased to 36.2% of sales in the first nine months of 1999
from 38.3% of sales in the comparable period of 1998. To improve

<PAGE>

overall profitability, one of the long-term objectives of
management is to control SG&A growth at a fraction of sales
growth. The Life Science segment grew SG&A expenditures at only
66% of sales growth. Clinical Diagnostics expenditures remain
virtually unchanged and Analytical Instruments expenditures
declined for the first nine months of 1999.

Consolidated R&D increased 5.4% for the first nine months of 1999
compared to the same period in 1998. Life Science and Clinical
Diagnostics each increased R&D investments as planned.
Analytical Instruments R&D expenditures declined across most
product lines due to the slowdown in the markets served and the
decision to adjust R&D expenditures to economic and market
conditions.

Corporate Results - Non-operating Items

Interest expense was $2.5 million, a slight decline from the
prior year, as a result of lower average borrowings. Borrowings
will increase due to the purchase of PSD. Accordingly, interest
expense will also increase significantly. Investment income
includes gains on sales of marketable securities and interest
income from short term investments. Investment income in both
years includes gains on sales of marketable securities. The
Company's portfolio was further reduced to lower total borrowings
in preparation of the refinancing necessary to conclude the
acquisition of PSD. Net other income and expense for the nine
months ended September 30, 1999 and 1998 includes goodwill
amortization and non-operating legal costs.

The Company's effective tax rate is unchanged at 29% for the year
ended September 30, 1999. The tax rate for both years reflects
the utilization of loss carryforwards, foreign sales corporation
benefits and foreign tax credits. No determination of the impact
to the Company's effective tax rate from the acquisition of PSD
has been completed; however, the rate may rise as limitations may
be imposed on the deductibility of some level of interest expense
and the amortization of certain intangibles.

Financial Condition

On July 3, 1999, the Company reached agreement to purchase PSD
and all its holdings including some ancillary assets from Sanofi-
Synthelabo S.A. and Institut Pasteur (see Note 8). The
acquisition was completed on October 1, 1999.

The Company became substantially leveraged as it entered into new
credit facilities. The Company entered into a $200 million
credit facility (consisting of a $100 million term loan and a
$100 million revolving credit line) on September 30, 1999,
replacing the $100 million credit agreement previously in place.
The new facility provides for borrowings on a secured basis

<PAGE>

through September 30, 2004. Interest is based upon the
Eurocurrency rate, the Federal Funds Effective rate or Bank One's
base rate.

The lenders have placed restrictions on the Company's ability to:
borrow further, service this and other debt, make expenditures
for capital improvements, pay dividends, repurchase the Company's
own stock and/or make strategic and tactical investments in
support of operating the business. The Company is also required
to comply with certain financial ratios. The amount of debt
undertaken in connection with this acquisition could materially
impact the financial condition of the Company should management's
plan for operating the new entity not be successful.

The Company as of October 1, 1999 had available approximately $50
million under its principal revolving credit agreement and cash
and cash equivalents of approximately $12 million. Marketable
securities have now been liquidated to a level the Company no
longer considers material to its working capital needs.

At September 30, 1999, consolidated accounts receivable decreased
by $0.8 million from December 31, 1998. The decrease represents
the net impact of a strengthened U.S. dollar lowering foreign
denominated receivables and a seasonal slowdown in remittances
attributed in part to summer holiday scheduling.

At September 30, 1999, consolidated net inventories were $4.0
million higher than at December 31, 1998. As planned, inventory
increased in the Clinical Diagnostics segment. Inventory for the
Clinical Diagnostics controls business, a growth area for the
Company, is characterized by long lead times and large infrequent
batch production which is necessary to meet customers
requirements.

Net capital expenditures totaled $17.9 million for the first nine
months of 1999 compared to $14.4 million for the same period of
1998. Capital expenditures include additions of reagent rental
equipment placed with Clinical Diagnostic customers who then

<PAGE>

commit to purchasing the Company's diagnostic reagents for
use.

The Board of Directors has authorized the Company to repurchase
up to $18 million of common stock over an indefinite period of
time. From July 1996 through September 1999, the Company has
repurchased 567,786 shares of Class A common stock and 30,000
shares of Class B common stock for a total of $14.1 million. The
new credit facilities restrict the Company's ability to
repurchase its own stock to an amount not to exceed $5 million in
the aggregate in a fiscal year. Share repurchases made during
the current fiscal year amount to $2.2 million.

Euro - A New European Currency

On January 1, 1999, certain member countries of the European
Union began to fix the conversion rates between their national
currencies and a common currency, the "Euro." Over the period
January 1, 1999 through January 1, 2002 participating countries
will gradually transition from their national currencies to the
Euro.

This transition will have business implications including the
need to adjust internal systems to accommodate the Euro and
cross-border price transparency. A group of Corporate and
European managers have been assigned the task of preparing and
accommodating the changes required to continue to do business in
the European Union. The Company does not presently expect that
the efforts involved will have a material impact on operations,
financial position or liquidity. There will be increased
competitive pressures, and marketing strategies will need to be
continuously evaluated until the transition is complete. As a
result of competitive forces and emerging government regulations,
the Company cannot guarantee that all problems will be foreseen
and remediated, and that no material disruption will occur.

Year 2000

The Year 2000 issue is the result of computer programs being
written using two rather than four digits to define the date.
Failure to recognize "00" as the year 2000 could result in a
temporary inability to conduct normal business activities.

Bio-Rad currently operates in a decentralized processing
environment. The Company, with the assistance of outside
consultants and contractors, is well underway with phased
identification, remediation, replacement, validation and
notification processes to minimize the potential disruption to
business from information technology and non-information
technology systems. The project start-up, inventory and
assessment phases are complete. Remediations or scheduled
replacements will be completed for each location prior to the

<PAGE>

Year 2000 deadline where significant. The Company is reviewing
in detail all aspects of the Year 2000 issue for the acquired
operations of PSD. Currently, risks appear to be equivalent to
those faced by Bio-Rad prior to the acquisition. No materially
significant amounts need to be spent on the Year 2000 issue prior
to December 31, 1999 as a result of the acquisition.

Bio-Rad's manufactured products have also been undergoing
assessment for Year 2000 readiness. Certain products Bio-Rad
manufactured in the past are not Year 2000 compliant. We have
instituted a program to replace relevant products.

The Company has identified significant suppliers and is
requesting information from them regarding the Year 2000
readiness of their products or services. The Company has not yet
received enough responses and now expects certain suppliers not
to confirm compliance or to respond timely. A material adverse
impact may not be avoided. It is not possible at this time to
value the amount of business that might be lost as a result of
Bio-Rad's business partners' failure to deliver products and
services after December 31, 1999. Additionally, global
infrastructure comprised of banking, transportation,
communication, power generation and ordinary and necessary
governmental activities are critical to the Company's operations.
Should any of these suppliers not be fully functional after 1999
the negative impact to the Company would be significant and
material.

The expenditures required in 1998 and 1999 to replace and
remediate Year 2000 non-compliant Bio-Rad information technology
systems, including equipment, is estimated at $8 million and
primarily deals with distribution system capabilities worldwide.
Over 95% of these costs have been incurred to date. Hardware and
software purchased and installed in connection with these
projects will provide both Year 2000 readiness and significant
additional functionality. Manufacturing systems have been
remediated at a cost that is not material to Bio-Rad overall;
these costs were included in operating results in 1997 and 1998.
While some systems enhancements or modifications have been
delayed to allow for the more significant Year 2000 remediation
to be completed, weighing both cost and benefit, Bio-Rad
management believes its response is prudent.

The Company as of this date has not identified the "most likely
worst case Year 2000 scenario." That scenario will be largely
dependent on the Company's significant worldwide suppliers and
its assessment of preparedness of the global infrastructure,
including multiple national governments. During the remainder of
1999 the Company will formulate and review additional contingency
plans based on the aforementioned significant supplier responses
and global infrastructure preparedness. The Company has
organized a group solely to respond rapidly to Bio-Rad technical

<PAGE>

information processing and communication exceptions. The Group
is expected to implement a reporting mechanism to quickly inform
management about those issues that might cause a deterioration in
Bio-Rad's operations or our ability to compete effectively.

New Financial Accounting Standards

In June 1998, the Financial Accounting Standards Board (FASB)
issued Statement of Financial Accounting Standards (SFAS) No.
133, "Accounting for Derivative Instruments and Hedging
Activities" effective for fiscal years beginning after June 15,
1999. The FASB has now delayed implementation to fiscal years
beginning after June 15, 2000. This statement proposes to
establish accounting and reporting standards requiring companies
to record all derivatives on the balance sheet as either assets
or liabilities and measure those instruments at fair value. The
manner in which companies are to record gains or losses resulting
from changes in the values of those derivatives depends on the
use of the derivative and whether it qualifies for hedge
accounting. The impact of SFAS No. 133 on the Company's
financial statements will depend on a variety of factors,
including future interpretive guidance from the FASB, the future
level of forecasted and actual foreign currency transactions, the
extent of the Company's hedging activities, the types of hedging
instruments used and the effectiveness of such instruments. The
Company does not expect the adoption of SFAS No. 133 to have a
material effect on its financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market
Risk

During the three months and nine months ended September 30, 1999,
there have been no material changes from the disclosures about
market risk provided in the Company's Annual Report on Form 10-K
for the year ended December 31, 1998. As a result of the new
credit facilities, Bio-Rad has become increasingly exposed to
increases in interest rates. The Company will be undertaking a
review of its options to fix a portion of its variable interest
rate long-term debt during the next several quarters.

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits

The following documents are filed as part of this report:

Exhibit No.

4.1 Credit Agreement dated as of September 30, 1999 among
Bio-Rad Laboratories, Inc., the lenders named therein,

<PAGE>

Banc One, N.A., as Administrative Agent, ABN AMRO Bank
N.V. as Syndication Agent, and Union Bank of
California, N.A. as Documentation Agent. Incorporated
by reference from the Exhibit 4.1 to the Company's
Form 8-K, dated October 1, 1999.

4.2 Senior Subordinated Credit Agreement dated as of
September 30, 1999 among Bio-Rad Laboratories, Inc.,
the lenders named therein and Banc One Capital
Markets, Inc., as Agent. Incorporated by reference
from Exhibit 4.2 to the Company's Form 8-K, dated
October 1, 1999.

4.3 Warrant Agreement among Bio-Rad Laboratories, Inc. and
Banc One Capital Markets, Inc. dated as of
September 30, 1999.

27.1 Financial Data Schedule.

(b) Reports on Form 8-K

Bio-Rad filed Form 8-K dated July 5, 1999, announcing that Bio-
Rad Sanofi-Synthelabo S.A. (Sanofi) and Institut Pasteur (IP)
have executed an agreement pursuant to which Bio-Rad shall
acquire Pasteur Sanofi Diagnostics S.A. from Sanofi and IP for an
aggregate purchase price not to exceed $210.00 million in cash.

<PAGE>

EXHIBIT 4.3

WARRANT AGREEMENT

among

BIO-RAD LABORATORIES, INC.

and

BANC ONE CAPITAL MARKETS, INC.,
Individually and as Agent

Dated as of September 30, 1999

<PAGE>

TABLE OF CONTENTS

Page
SECTION 1. Warrant Certificates. . . . . . . . . . . . . . . . . 1
SECTION 2. Execution of Warrant Certificates . . . . . . . . . . 1
SECTION 3. Registration . . . . . . . . . . . . . . . . . . . . 2
SECTION 4. Registration of Transfers and Exchanges . . . . . . . 2
SECTION 5. Warrants; Exercise of Warrants . . . . . . . . . . . 4
SECTION 6. Payment of Taxes . . . . . . . . . . . . . . . . . . 6
SECTION 7. Mutilated or Missing Warrant Certificates . . . . . . 6
SECTION 8. Reservation of Warrant Shares . . . . . . . . . . . . 7
SECTION 9. Obtaining Stock Exchange Listings . . . . . . . . . . 7
SECTION 10. Adjustment of Exercise Price and Number
of Warrant Shares Issuable . . . . . . . . . . . 8
(a) Adjustment for Change in Capital Stock . . . 8
(b) Adjustment for Rights Issue . . . . . . . . . 9
(c) Adjustment for Other Distributions . . . . . 10
(d) Adjustment for Common Stock Issue . . . . . 11
(e) Adjustment for Convertible Securities Issue . 13
(f) Current Market Price . . . . . . . . . . . 15
(g) Consideration Received . . . . . . . . . . . 16
(h) When De Minimis Adjustment May Be Deferred . 16
(i) When No Adjustment Required . . . . . . . . 17
(j) Notice of Adjustment . . . . . . . . . . . . 17
(k) Voluntary Reduction . . . . . . . . . . . . 17
(l) Reorganization of the Company . . . . . . . 17
(m) When Issuance or Payment May Be Deferred . . 18
(n) Adjustment in Number of Shares . . . . . . 18
(o) Form of Warrants . . . . . . . . . . . . . 19
(p) Regulation Y Limitations . . . . . . . . . 19
SECTION 11. No Dilution or Impairment . . . . . . . . . . . . . 20
SECTION 12. Fractional Interests . . . . . . . . . . . . . . . . 21
SECTION 13. Notices to Warrant Holders . . . . . . . . . . . . . 21
SECTION 14. Registration Rights . . . . . . . . . . . . . . . . 23
(a) Intentionally omitted . . . . . . . . . . . . 23
(b) Demand Registration . . . . . . . . . . . . 23
(c) Piggy-Back Registration . . . . . . . . . . . 24
(d) Registration Procedures . . . . . . . . . . . 26
(e) Indemnification . . . . . . . . . . . . . . . 29
(f) Certain Definitions . . . . . . . . . . . . . 32

<PAGE>

SECTION 15. Notices to Company and Warrant Holder . . . . . . . 33
SECTION 16. Warrant Agent . . . . . . . . . . . . . . . . . . . 34
SECTION 17. Supplements and Amendments . . . . . . . . . . . . . 35
SECTION 18. Successors . . . . . . . . . . . . . . . . . . . . . 35
SECTION 19. Termination . . . . . . . . . . . . . . . . . . . . 35
SECTION 20. Governing Law . . . . . . . . . . . . . . . . . . . 35
SECTION 21. Benefits of This Agreement . . . . . . . . . . . . . 35
SECTION 22. Counterparts . . . . . . . . . . . . . . . . . . . . 35

<PAGE>

This WARRANT AGREEMENT is dated as of September 30, 1999 and
entered into by and among Bio-Rad Laboratories, Inc., a Delaware corporation
(the "Company"), and Banc One Capital Markets, Inc. ("BOCM"), individually
and as Agent on behalf of the Lenders under the Bridge Loan Agreement
referred to below (the Agent ).

Terms defined in the Senior Subordinated Credit Agreement (the
"Bridge Loan Agreement") dated as of the date hereof among the Company, the
Agent and the Lenders, unless defined herein, are used as defined in the
Bridge Loan Agreement. Certain other capitalized terms used herein are
defined in Section 14(f) hereof.

WHEREAS, the Company proposes to issue Warrants, as hereinafter
described (the "Warrants"), to purchase up to 10% of the total number of
fully-diluted shares of capital stock of the Company, which Warrants may be
exercised to purchase shares of Class A Common Stock, par value $1.00 per
share (the "Common Stock"), of the Company (the Common Stock issuable on
exercise of the Warrants being referred to herein as the "Warrant Shares")
in connection with the borrowing of $100 million of senior subordinated
loans under the Bridge Loan Agreement and/or the refinancing of such
borrowings with each Warrant entitling the Holder thereof to purchase
one Warrant Share.

NOW, THEREFORE, in consideration of the premises and the mutual
agreements herein set forth, the parties hereto agree as follows:

SECTION 1. Warrant Certificates. The certificates evidencing
the Warrants (the "Warrant Certificates") shall be issued in registered form
only and shall be substantially in the form set forth in Exhibit A-1 attached
hereto with respect to the initial Warrants issued by the Company and
deposited into escrow on the Closing Date and shall be substantially in the
form of Exhibit A-2 attached hereto with respect to the Warrants from time to
time released from escrow on each Warrant Release Date, in each case as
contemplated by and in accordance with the Escrow Agreement.

SECTION 2. Execution of Warrant Certificates. Warrant
Certificates shall be signed on behalf of the Company by its Chairman of the
Board or its President or a Vice President and by its Secretary or an
Assistant Secretary. Each such signature upon the Warrant Certificates may
be in the form of a facsimile signature of the present or any future
Chairman of the Board, President, Vice President, Secretary or Assistant

<PAGE>

Secretary and may be imprinted or otherwise reproduced on the Warrant
Certificates and for the purpose the Company may adopt and use the facsimile
signature of any person who shall have been Chairman of the Board,
President, Vice President, Secretary or Assistant Secretary, notwithstanding
the fact that at the time the Warrant Certificates shall be delivered or
disposed of he or she shall have ceased to hold such office.

In case any officer of the Company who shall have signed any of
the Warrant Certificates shall cease to be such officer before the Warrant
Certificates so signed shall have been disposed of by the Company, such
Warrant Certificates nevertheless may be delivered or disposed of as though
such person had not ceased to be such officer of the Company; and any
Warrant Certificate may be signed on behalf of the Company by any person
who, at the actual date of the execution of such Warrant Certificate, shall
be a proper officer of the Company to sign such Warrant Certificate,
although at the date of the execution of this Warrant Agreement any such
person was not such officer.

SECTION 3. Registration. The Company shall number and register
the Warrant Certificates in a register as they are issued. Warrants shall
be issued on the Closing Date and released from escrow, in each case in
accordance with Section 12 of the Bridge Loan Agreement. The Company may
deem and treat the registered holder(s) of the Warrant Certificates (the
"Holder(s)") as the absolute owner(s) thereof (notwithstanding any notation
of ownership or other writing thereon made by anyone), for all purposes, and
shall not be affected by any notice to the contrary. The Company shall act
as the registrar for the Warrants.

SECTION 4. Registration of Transfers and Exchanges. Concurrent
with the surrender of any outstanding Warrant Certificate(s) accompanied by
a written instrument or instruments of transfer substantially in the form of
Exhibit B hereto, duly executed by the registered Holder or Holders thereof
or by the duly appointed legal representative thereof or by a duly authorized
attorney, the Company shall promptly register the transfer of any outstanding
Warrant Certificates in a Warrant register to be maintained by the Company
and promptly issue a new Warrant Certificate in the name of the
transferee(s). The surrendered Warrant Certificate(s) shall thereupon be
cancelled and disposed of by the Company.

Each of the Holders represents and warrants to the Company that:

2
<PAGE>

(a) such Holder is an institutional accredited investor within the
meaning of Regulation D of the Securities Act and the Warrants to be acquired
by it pursuant to Section 12 of the Bridge Loan Agreement are being acquired
for its own account and without a view to, or for resale in connection with,
any distribution thereof or any interest therein; provided that the
provisions of this Section shall not prejudice such Holder s right at all
times to sell or otherwise dispose of all or any part of the Warrants so
acquired pursuant to a registration under the Securities Act or an exemption
from such registration available under the Securities Act;

(b) such Holder has such knowledge and experience in financial and
business matters so as to be capable of evaluating the merits and risks of
its investment in the Warrants, such Holder is capable of bearing the
economic risks of such investment and such Holder has had the opportunity
to conduct its own due diligence investigation in relation to its purchase
of the Warrants hereunder;

(c) no part of the funds used by such Holder to purchase the Warrants
hereunder constitutes assets of any plan (as defined in Section 4975 of the
Internal Revenue Code).

The Holders agree that prior to any proposed transfer of the
Warrant or of the Warrant Shares, if such transfer is not made pursuant to an
effective Registration Statement under the Securities Act, pursuant to Rule
144 or Rule 144A under the Securities Act, or an opinion of counsel,
reasonably satisfactory in form and substance to the Company, that the
Warrant or Warrant Shares may be sold publicly without registration under
the Securities Act, the Holder will, if requested by the Company, deliver
to the Company:

(1) an investment covenant substantially similar to Section
4(a) above signed by the proposed transferee;

(2) an agreement by such transferee to the impression of the
restrictive investment legend set forth below on the Warrant or the
Warrant Shares;

(3) an agreement by such transferee that the Company may place
a notation in the stock books of the Company or a "stop transfer order"
with any transfer agent or registrar with respect to the Warrant
Shares; and

<PAGE>

(4) an agreement by such transferee to be bound by the
provisions of this Section 4 relating to the transfer of such Warrant
or Warrant Shares.

The Holders agree that each Warrant Certificate and any
certificate representing the Warrant Shares will bear the following legend:

"NEITHER THE ISSUANCE OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE (AND ANY PREDECESSOR) NOR THE ISSUANCE OF ANY
SECURITIES ISSUABLE UPON EXERCISE HEREOF HAS BEEN REGISTERED UNDER
SECTION 5 OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE "SECURITIES ACT"), OR PURSUANT TO THE SECURITIES LAWS OF ANY
STATE, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR
OTHERWISE TRANSFERRED EXCEPT PURSUANT TO (i) A REGISTRATION
STATEMENT IN EFFECT WITH RESPECT TO SUCH SECURITIES UNDER THE
SECURITIES ACT AND THE RULES AND REGULATIONS THEREUNDER OR (ii) AN
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND ANY APPLICABLE STATE SECURITIES LAWS."

Subject to the foregoing provisions, Warrant Certificates may be
exchanged at the option of the Holder(s) thereof, when surrendered to the
Company at its office for another Warrant Certificate or other Warrant
Certificates of the like tenor and representing in the aggregate a like
number of Warrants. Warrant Certificates surrendered for exchange shall
be, upon issuance of the new Warrant Certificate(s), cancelled and disposed
of by the Company.

On delivery of the Warrants by the Escrow Agent to the Warrant
Holder or Holders pursuant to the Escrow Agreement, each Warrant Holder will
have registration rights with respect to the Warrant Shares as set forth in
Section 14 hereof.

SECTION 5. Warrants; Exercise of Warrants. Subject to the
terms of this Agreement, each Holder shall have the right, which may be
exercised commencing at the opening of business on the date the Escrow Agent
delivers Warrants to such Holder in compliance with the terms of the Escrow
Agreement and the Bridge Loan Agreement and until 5:00 p.m., Chicago time,

<PAGE>

on September 30, 2009 to receive from the Company the number of fully paid
and nonassessable Warrant Shares which the Holder may at the time be
entitled to receive on exercise of such Warrants and payment of the Exercise
Price then in effect for such Warrant Shares. Each Warrant not exercised
prior to 5:00 p.m., Chicago time, on September 30, 2009 shall become void
and all rights thereunder and all rights in respect thereof under this
agreement shall cease as of such time. No adjustments as to dividends will
be made upon exercise of the Warrants.

A Warrant may be exercised upon surrender to the Company at its
office designated for such purpose (the address of which is set forth in
Section 15 hereof) of the certificate or certificates evidencing the
Warrants to be exercised with the form of election to purchase on the
reverse thereof duly filled in and signed, which signature shall be
guaranteed by a bank or trust company having an office or correspondent
in the United States or a broker or dealer which is a member of a
registered securities exchange or the National Association of Securities
Dealers, Inc., and upon payment to the Company of the exercise price
(the "Exercise Price") which is set forth in the forms of Warrant
Certificates attached hereto as Exhibit A-1 and Exhibit A-2,
as adjusted as herein provided, for the number of Warrant Shares
in respect of which such Warrants are then exercised. Payment of
the aggregate Exercise Price shall be made in cash or by certified
or official bank check to the order of the Company. In lieu of exercising
a Warrant by paying in full the Exercise Price plus transfer taxes (if
applicable pursuant to Section 6), if any, the Holder may, from time
to time, convert such Warrant, in whole or in part, into a number of
shares of Common Stock determined by dividing (a) the aggregate current
market price of the number of shares represented by the Warrants converted,
minus the aggregate Exercise Price for such shares, minus transfer taxes,
if any, by (b) the current market price of one Share. The current market
price shall be determined pursuant to Section 10(f).

Subject to the provisions of Section 6 hereof, upon such
surrender of Warrants and payment of the Exercise Price, the Company shall
issue and cause to be delivered with all reasonable dispatch to or upon
the written order of the Holder and in such name or names as the Holder
may designate, a certificate or certificates for the number of full Warrant
Shares issuable upon the exercise of such Warrants together with cash as
provided in Section 12; provided, however, that if any consolidation, merger
or lease or sale of assets is proposed to be effected by the Company as
described in subsection (l) of Section 10 hereof, or a tender offer or an
exchange offer for shares of Common Stock of the Company shall be made,
upon such surrender of Warrants and payment of the Exercise Price as

<PAGE>

aforesaid, the Company shall, as soon as possible, but in any event not
later than two Business Days thereafter, issue and cause to be delivered
the full number of Warrant Shares issuable upon the exercise of such
Warrants in the manner described in this sentence together with cash
as provided in Section 12. Such certificate or certificates shall be
deemed to have been issued and any person so designated to be named therein
shall be deemed to have become a holder of record of such Warrant Shares
as of the date of the surrender of such Warrants and payment of the
Exercise Price.

The Warrants shall be exercisable, at the election of the
Holders thereof, either in full or from time to time in part (provided
that Warrants shall be exercisable in multiples of 100 Warrant Shares unless
all of the Warrant Shares evidenced by a particular Warrant Certificate are
being exercised) and, in the event that a Warrant Certificate is exercised
in respect of fewer than all of the Warrant Shares issuable on such exercise
at any time prior to the date of expiration of the Warrants, a new Warrant
Certificate evidencing the remaining Warrant or Warrants will be issued and
delivered pursuant to the provisions of this Section and of Section 2
hereof.

All Warrant Certificates surrendered upon exercise of Warrants
shall be cancelled and disposed of by the Company. The Company shall keep
copies of this Agreement and any notices given or received hereunder
available for inspection by the Holders during normal business hours at its
office.

SECTION 6. Payment of Taxes. The Company will pay all
documentary stamp taxes attributable to the initial issuance of Warrant
Shares upon the exercise of Warrants; provided, however, that the Company
shall not be required to pay any tax or taxes which may be payable in
respect of any transfer involved in the issue of any Warrant Certificates
or any certificates for Warrant Shares in a name other than that of the
registered Holder of a Warrant Certificate surrendered upon the exercise of
a Warrant, and the Company shall not be required to issue or deliver such
Warrant Certificates unless or until the Person or Persons requesting the
issuance thereof shall have paid to the Company the amount of such tax or
shall have established to the satisfaction of the Company that such tax has
been paid.

SECTION 7. Mutilated or Missing Warrant Certificates. In case
any of the Warrant Certificates shall be mutilated, lost, stolen or
destroyed, the Company shall issue, in exchange and substitution for and
upon cancellation of the mutilated Warrant Certificate, or in lieu of and
substitution for the Warrant Certificate lost, stolen or destroyed, a new
Warrant Certificate of like tenor and representing an equivalent number of

<PAGE>

Warrants, but only upon surrender of the mutilated certificate or upon
receipt of evidence reasonably satisfactory to the Company of such loss,
theft or destruction of such Warrant Certificate as applicable and
indemnity, if requested, also reasonably satisfactory to it.

SECTION 8. Reservation of Warrant Shares. The Company will at
all times reserve and keep available, free from preemptive rights, out of
the aggregate of its authorized but unissued Common Stock or its authorized
and issued Common Stock held in its treasury, for the purpose of enabling
it to satisfy any obligation to issue Warrant Shares upon exercise of
Warrants, the maximum number of shares of Common Stock which may then be
deliverable upon the exercise of all outstanding Warrants.

The Company or, if appointed, the transfer agent for the Common
Stock (the "Transfer Agent") and every subsequent transfer agent for any
shares of the Company's capital stock issuable upon the exercise of any of
the rights of purchase aforesaid will be irrevocably authorized and
directed at all time to reserve such number of authorized shares as shall be
required for such purpose. The Company will keep a copy of this Agreement
on file with the Transfer Agent and with every subsequent transfer agent
for any shares of the Company's capital stock issuable upon the exercise of
the rights of purchase represented by the Warrants. The Company will
furnish such Transfer Agent a copy of all notices of adjustments and
certificates related thereto, transmitted to each Holder pursuant to
Section 15 hereof.

Before taking any action which would cause an adjustment
pursuant to Section 10 hereof to reduce the Exercise Price below the then
par value (if any) of the Warrant Shares, the Company will take any
corporate action which may, in the opinion of its counsel (which may be
counsel employed by the Company), be necessary in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares
at the Exercise Price as so adjusted.

The Company covenants that all Warrant Shares which may be
issued upon exercise of Warrants will, upon issue and payment therefor, be
fully paid, nonassessable, free of preemptive rights and free from all
taxes, liens, charges and security interests with respect to the issue
thereof.

SECTION 9. Obtaining Stock Exchange Listings. The Company will
from time to time take all action which may be necessary so that the Warrant
Shares, immediately upon their issuance upon the exercise of Warrants, will

<PAGE>

be listed on the principal securities exchanges and markets within the
United States of America, if any, on which other shares of Common Stock
are then listed.

SECTION 10. Adjustment of Exercise Price and Number of Warrant
Shares Issuable. The Exercise Price and the number of the Warrant Shares
issuable upon the exercise of each Warrant are subject to adjustment from
time to time upon the occurrence of the events enumerated in this Section.
For purposes of this Section 10, "Common Stock" means shares now or
hereafter authorized of any class of common stock of the Company and any
other stock of the Company, however designated, that has the right (subject
to any prior rights of any class or series of preferred stock) to
participate in any distribution of the assets or earnings of the Company
without limit as to percentage or per share amount.

(a) Adjustment for Change in Capital Stock.

If the Company:

(1) pays a dividend or makes a distribution on its Common Stock
in shares of its Common Stock;

(2) subdivides its outstanding shares of Common Stock into a
greater number of shares;

(3) combines its outstanding shares of Common Stock into a
smaller number of shares;

(4) makes a distribution on its Common Stock in shares of its
capital stock other than Common Stock or preferred stock; or

(5) issues by reclassification of its Common Stock any shares of
its capital stock;

then the Exercise Price and the number and kind of shares of capital stock
of the Company issuable upon the exercise of a Warrant as in effect
immediately prior to such action shall be proportionately adjusted so that
the Holder of any Warrant thereafter exercised may receive the aggregate
number and kind of shares of capital stock of the Company which he or she
would have owned immediately following such action if such Warrant had been
exercised immediately prior to such action.

<PAGE>

The adjustment shall become effective immediately after the
record date in the case of a dividend or distribution and immediately after
the effective date in the case of a subdivision, combination or
reclassification.

If after an adjustment a Holder of a Warrant upon exercise of
it may receive shares of two or more classes of capital stock of the
Company, the Company shall determine the allocation of the adjusted
Exercise Price between the classes of capital stock. After such
allocation, the exercise privilege and the Exercise Price of each class
of capital stock shall thereafter be subject to adjustment on terms
comparable to those applicable to Common Stock in this Section 10.

Such adjustment shall be made successively whenever any event
listed above shall occur.

(b) Adjustment for Rights Issue.

If the Company distributes any rights, options or warrants to
all holders of its Common Stock entitling them for a period expiring within
60 days after the record date mentioned below to purchase shares of Common
Stock at a price per share less then the current market price per share on
that record date, the Exercise Price shall be adjusted in accordance with
the formula:

O + N x P
_____
E' = E x M
_________
O + N

where:

E' = the adjusted Exercise Price.

E = the current Exercise Price.

O = the number of shares of Common Stock outstanding on the
record date.

N = the number of additional shares of Common Stock offered
pursuant to such rights issuance.

P = the offering price per share of the additional shares.

<PAGE>

M = the current market price per share of Common Stock on the
record date.

The adjustment shall be made successively whenever any such
rights, options or warrants are issued and shall become effective
immediately after the record date for the determination of stockholders
entitled to receive the rights, options or warrants. If at the end of the
period during which such rights, options or warrants are exercisable, not
all rights, options or warrants shall have been exercised, the Exercise
Price shall be immediately readjusted to what it would have been if "N"
in the above formula had been the number of shares actually issued.

If the Company distributes to all holders of its Common Stock
any of its assets (including but not limited to cash, but excluding
ordinary dividends), debt securities, preferred stock, or any rights or
warrants to purchase debt securities, preferred stock, assets or other
securities of the Company, the Exercise Price shall be adjusted in
accordance with the formula:

E' = E x M - F
_____
M

where:

E' = the adjusted Exercise Price.

E = the current Exercise Price.

M = the current market price per share of Common Stock on the
record date mentioned below.

F = the fair market value on the record date of the assets,
securities, rights or warrants applicable to one share
of Common Stock. The board of directors of the Company
(the "Board of Directors") shall determine the fair
market value in good faith.

<PAGE>

The adjustment shall be made successively whenever any such
distribution is made and shall become effectively immediately after the
record date for the determination of stockholders entitled to receive the
distribution.

This subsection does not apply to rights, options or warrants
referred to in subsection (b) of this Section 10.

(d) Adjustment for Common Stock Issue.

If the Company issues Common Stock for a consideration per
share less than the current market price per share on the date the Company
fixes the offering price of such additional shares, the Exercise Price
shall be adjusted in accordance with the formula:

E' = E x O + P
___
M
________
A

where:

E' = the adjusted Exercise Price.

E = the then current Exercise Price.

O = the number of shares outstanding immediately prior to the
issuance of such additional shares.

P = the aggregate consideration received for the issuance of
such additional shares.

M = the current market price per share on the date of
issuance of such additional shares.

A = the number of shares outstanding immediately after the
issuance of such additional shares.

The adjustment shall be made successively whenever any such
issuance is made, and shall become effective immediately after such
issuance.

<PAGE>

This subsection (d) does not apply to:

(1) any of the transactions described in subsections (a), (b)
and (c) of this Section 10,

(2) the exercise of Warrants, or upon the issuance of any Common
Stock which is issued pursuant to the exercise of any options, warrants
or other subscription or purchase rights or pursuant to the exercise of
any conversion or exchange rights in any convertible securities
described in subsection (e) of this Section 10, if an adjustment to the
Exercise Price shall previously have been made hereunder upon the
issuance of such options, warrants or other rights or upon the issuance
of such convertible securities.

(3) Common Stock issued to the Company's employees, consultants
or advisors under bona fide employee benefit plans adopted by the Board
of Directors and approved by the holders of Common Stock when required
by law, if such Common Stock would otherwise be covered by this
subsection (d) (but only to the extent that the aggregate number of
shares excluded hereby and issued after the date of this Warrant
Agreement shall not exceed 5% of the Common Stock outstanding on a fully
diluted basis at the time of the adoption of any such plan, exclusive of
anti-dilution adjustments thereunder and exclusive of the Warrants and
Warrant Shares contemplated hereunder),

(4) Common Stock issued to shareholders of any person which
merges into the Company in proportion to their stock holdings of such
person immediately prior to such merger, upon such merger, provided the
Board of Directors determines such merger is on fair and reasonable
terms to the Company,

(5) Common Stock issued in a bona fide public offering pursuant
to a firm commitment underwriting,

(6) Common Stock issued upon the exercise of rights or warrants
issued to holders of Common Stock to the extent an adjustment was made
under subsection (b) of this Section 10, and

(7) Common Stock issued to Persons who are not Affiliates of the
Company in a bona fide private placement through a placement agent that

<PAGE>

is a member firm of the NASD (except to the extent that any discount
from the current market price attributable to restrictions on trans-
ferability of the Common Stock, as determined in good faith by the Board
of Directors, shall exceed 15%).

(e) Adjustment for Convertible Securities Issue.

If the Company issues any securities convertible into or
exchangeable for Common Stock (other than securities issued in transactions
described in subsections (b) and (c) and the exceptions to subsection (d)
of this Section 10) for a consideration per share of Common Stock initially
deliverable upon conversion or exchange of such securities less than the
current market price per share on the date of issuance of such securities,
the Exercise Price shall be adjusted in accordance with this formula:

<PAGE>

E' = E x O + P
_
M
_____
O + D

where:

E' = the adjusted Exercise Price.

E = the then current Exercise Price.

O = the number of shares outstanding immediately prior to the
issuance of such securities.

P = the aggregate consideration received for the issuance of
such securities.

M = the current market price per share on the date of
issuance of such securities.

D = the maximum number of shares deliverable upon conversion
or in exchange for such securities at the initial
conversion or exchange rate.

The adjustment shall be made successively whenever any such
issuance is made, and shall become effective immediately after such
issuance.

If all of the Common Stock deliverable upon conversion or
exchange of such securities have not been issued when such securities
are no longer outstanding, then the Exercise Price shall promptly be
readjusted to the Exercise Price which would then be in effect had the
adjustment upon the issuance of such securities been made on the basis
of the actual number of shares of Common Stock issued upon conversion
or exchange of such securities.

This subsection (e) does not apply to:

(1) convertible securities issued to shareholders of any person
which merges into the Company, or with a subsidiary of the Company, in
proportion to their stock holdings of such person immediately prior to

<PAGE>

such merger, upon such merger, provided the Board of Directors determines
such merger is on fair and reasonable terms to the Company,

(2) convertible securities issued in a bona fide public offering
pursuant to a firm commitment underwriting, or

(3) convertible securities issued to Persons who are not
Affiliates of the Company in a bona fide private placement through a
placement agent that is a member firm of the NASD (except to the extent
that any discount from the current market price attributable to
restrictions on transferability of Common Stock issuable upon conversion,
as determined in good faith by the Board of Directors, shall exceed 15%).

(f) Current Market Price.

In subsections (b), (c), (d) and (e) of this Section 10 the
current market price per share of Common Stock on any date is the average of
the Quoted Prices of the Common Stock for 30 consecutive trading days
commencing 45 trading days before the date in question. The "Quoted
Price" of the Common Stock is the last reported sales price of the Common
Stock as reported by the American Stock Exchange ("AMEX"). If the Common
Stock is no longer isted on AMEX, then the Quoted Price shall be the last
reported sales price as reported by any other national securities exchange
on which the Common Stock is then listed, or the last reported bid
quotation of the Common Stock if it is then quoted on a national quotation
system. If the Common Stock is neither so listed nor quoted, then the
Board of Directors of the Company shall determine the current market
price of the Common Stock on the basis of such quotations, appraisals
and/or evaluations as it in reasonable good faith considers appropriate;
provided that if Holders of a majority in interest of the outstanding
Warrants objects in writing to such determination within 20 Business Days
after receiving notice of any adjustment based in part on such
determination, the current market price shall be determined by a nationally
recognized investment banking firm jointly selected within 20 Business Days
of such objection by the Company and such Holders (acting by a majority vote)
or, if no such joint selection can be agreed upon, by an investment banking
firm, selected by the American Arbitration Association (at the Company's
expense if the investment banker's determination is less than the Company's
determination, and at the expense of the objecting Holders in proportion to
their interests if the investment banker's determination is equal to or
greater than the Company's determination).

<PAGE>

(g) Consideration Received.

For purposes of any computation respecting consideration received
pursuant to subsections (d) and (e) of this Section 10, the following shall
apply:

(1) in the case of the issuance of shares of Common Stock for
cash, the consideration shall be the amount of such cash, provided that
in no case shall any deduction be made for any commissions, discounts or
other expenses incurred by the Company for any underwriting of the issue
or otherwise in connection therewith;

(2) in the case of the issuance of shares of Common Stock for a
consideration in whole or in part other than cash, the consideration
other than cash shall be deemed to be the fair market value thereof as
determined in good faith by the Board of Directors (irrespective of the
accounting treatment thereof), whose determination shall be conclusive,
and described in a Board Resolution, subject to the rights of a majority
in interest of the outstanding Warrants to object as provided in clause
(f) above, in which case fair market value shall be determined pursuant
to the procedure specified therein;

(3) in the case of the issuance of securities convertible into
or exchangeable for shares, the aggregate consideration received
therefor shall be deemed to be the consideration received by the Company
for the issuance of such securities plus the additional minimum
consideration, if any, to be received by the Company upon the conversion
or exchange thereof (the consideration in each case to be determined in
the same manner as provided in clauses (1) and (2) of this subsection).

(h) When De Minimis Adjustment May Be Deferred.

No adjustment in the Exercise Price need be made unless the
adjustment would require an increase or decrease of at least 1% in the
Exercise Price. Any adjustments that are not made shall be carried forward
and taken into account in any subsequent adjustment.

All calculations under this Section 10 shall be made to the
nearest one cent (or, for purposes of subsection (o) of this Section 10,
1/1000th of a cent) or to the nearest 1/100th of a share, as the case may
be.

<PAGE>

(i) When No Adjustment Required.

No adjustment need be made for a transaction referred to in
subsections (a), (b), (c), (d) or (e) of this Section 10 if Holders are to
participate in the transaction on a basis and with notice that the Board of
Directors determines to be fair and appropriate in light of the basis and
notice on which holders of Common Stock participate in the transaction.

No adjustment need be made for rights to purchase Common Stock
pursuant to a Company plan for reinvestment of dividends or interest.

No adjustment need be made for a change in the par value or no
par value of the Common Stock.

To the extent the Warrants become convertible into cash, no
adjustment need be made thereafter as to the cash. Interest will not
accrue on the cash.

(j) Notice of Adjustment.

Whenever the Exercise Price is adjusted, the Company shall
provide the notices required by Section 13 hereof.

(k) Voluntary Reduction.

The Company from time to time may reduce the Exercise Price by
any amount for any period of time if the period is at least 20 days and if
the reduction is irrevocable during the period; provided, however, that in
no event may the Exercise Price be less than the par value of a share of
Common Stock.

Whenever the Exercise Price is reduced, the Company shall mail to
Warrant Holders a notice of the reduction. The notice shall state the
reduced Exercise Price and the period it will be in effect.

A reduction of the Exercise Price does not change or adjust the
Exercise Price otherwise in effect for purposes of subsections (a), (b),
(c), (d) and (e) of this Section 10.

(l) Reorganization of the Company.

<PAGE>

If the Company consolidates or merges with or into, or
transfers or leases all or substantially all its assets to, any Person,
upon consummation of such transaction the Warrants shall automatically
become exercisable for the kind and amount of securities, cash or other
assets which the Holder of a Warrant would have owned immediately after
the consolidation, merger, transfer or lease if the Holder had exercised
the Warrant immediately before the effective date of the transaction.
Concurrently with the consummation of such transaction, the corporation
formed by or surviving any such consolidation or merger if other than the
Company, or the Person to which such sale or conveyance shall have been
made, shall enter into a supplemental Warrant Agreement so providing and
further providing for adjustments which shall be as nearly equivalent as
may be practical to the adjustments provided for in this Section. The
successor Company shall mail to Holders a notice describing the
supplemental Warrant Agreement.

If the issuer of securities deliverable upon exercise of
Warrants under the supplemental Warrant Agreement is an affiliate of
the formed, surviving, transferee or lessee corporation, that issuer
shall join in the supplemental Warrant Agreement.

If this subsection (1) applies, subsections (a), (b), (c),
(d) and (e) of this Section 10 do not apply.

(m) When Issuance or Payment May Be Deferred.

In any case in which this Section 10 shall require that an
adjustment in the Exercise Price be made effective as of a record date
for a specified event, the Company may elect to defer until the occurrence
of such event (i) issuing to the Holder of any Warrant exercised after such
record date the Warrant Shares and other capital stock of the Company, if
any, issuable upon such exercise over and above the Warrant Shares and
other capital stock of the Company, if any, issuable upon such exercise on
the basis of the Exercise Price and (ii) paying to such Holder any amount
in cash in lieu of a fractional share pursuant to Section 12; provided,
however, that the Company shall deliver to such Holder a due bill or other
appropriate instrument evidencing such Holder's right to receive such
additional Warrant Shares, other capital stock and cash upon the occurrence
of the event requiring such adjustment.

(n) Adjustment in Number of Shares.

<PAGE>

Upon each adjustment of the Exercise Price pursuant to this
Section 10, each Warrant outstanding prior to the making of the adjustment
in the Exercise Price shall thereafter evidence the right to receive upon
payment of the adjusted Exercise Price that number of shares of Common
Stock (calculated to the nearest hundredth) obtained from the following
formula:

N' = N x E
_
E'

where:

N' = the adjusted number of Warrant Shares issuable upon exercise
of a Warrant by payment of the adjusted Exercise Price.

N = the number of Warrant Shares previously issuable upon
exercise of a Warrant by payment of the Exercise Price prior
to adjustment.

E' = the adjusted Exercise Price.

E = the Exercise Price prior to adjustment.

(o) Form of Warrants.

Irrespective of any adjustments in the Exercise Price or the
number or kind of shares purchasable upon the exercise of the Warrants,
Warrants theretofore or thereafter issued may continue to express the same
price and number and kind of shares as are stated in the Warrants initially
issuable pursuant to this Agreement.

(p) Regulation Y Limitations.

If the holder of any Warrant is a Regulation Y Holder and is
prevented by the BHC Act from receiving any payment, dividend, distribution
or other consideration that the Company is required or permitted to make
under any provision hereof (including, without limitation, receiving Warrant
Shares pursuant to the proviso in the third paragraph of Section 5 hereof)
then, notwithstanding anything to the contrary contained or implied herein,
the Company shall (unless the applicable provision hereof provides an
alternative to such payment, dividend, distribution or other consideration
at the Company's option and the Company elects such alternative) structure

<PAGE>

the affected transaction so that such Regulation Y Holder receives
substantially equivalent consideration that is not prohibited by the
BHC Act.

As used in this clause (p),

"BHC Act" means the Bank Holding Company Act of 1956, as
amended, or any similar or successor law, and the rules and regulations
promulgated thereunder (including, without limitation, Regulation Y
thereunder), all as the same may be in effect from time to time.

"Regulation Y Holder" means any holder of a Warrant that is a
"bank holding company" (within the meaning of the BHC Act) or a subsidiary or
affiliate thereof subject to the BHC Act.

SECTION 11. No Dilution or Impairment. (a) If any event
shall occur as to which the provisions of Section 10 are not strictly
applicable but the failure to make any adjustment would adversely affect
the purchase rights represented by the Warrants in accordance with the
essential intent and principles of such Section, then, in each such case,
the Company shall appoint an investment banking firm of recognized national
standing that does not (or whose directors, officers, employees, affiliates
or stockholders do not) have a direct or material indirect financial
interest in the Company or any of its Subsidiaries, who has not been,
and, at the time it is called upon to give independent the opinion
described below, is not (and none of its directors, officers, employees,
affiliates or stockholders are) a promoter, director or officer of the
Company or any of its Subsidiaries, which shall give its opinion upon
the adjustment, if any, on a basis consistent with the essential intent
and principles established in Section 10, necessary to preserve,
without dilution, the purchase rights, represented by this Warrant. Upon
receipt of such opinion, the Company will promptly mail a copy thereof
to the Holders and shall make the adjustments described therein.

(b) The Company will not, by amendment of its certificate of
incorporation or through any consolidation, merger, reorganization,
transfer of assets, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of the Warrants, but will at all times
in reasonable good faith assist in the carrying out of all such terms
and in the taking of all such action as may be necessary or appropriate
in order to protect the rights of the Holders against dilution or other
impairment. Without limiting the generality of the foregoing, the Company
(1) will take all such action as may be necessary or appropriate in order

<PAGE>

that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock on the exercise of the Warrants from
time to time outstanding and (2) will not take any action which results
in any adjustment of the Exercise Price if the total number of Warrant
Shares issuable after the action upon the exercise of all of the Warrants
would exceed the total number of shares of Common Stock then authorized
by the Company's certificate of incorporation and available for the
purposes of issue upon such exercise. A consolidation, merger, reorganization
or transfer of assets involving the Company covered by Section 10(1) shall
not be prohibited by or require any adjustment under this Section 11.

SECTION 12. Fractional Interests. The Company shall not be
required to issue fractional Warrant Shares on the exercise of Warrants.
If more than one Warrant shall be presented for exercise in full at the
same time by the same Holder, the number of full Warrant Shares which shall
be issuable upon the exercise thereof shall be computed on the basis of
the aggregate number of Warrant Shares purchasable on exercise of the
Warrants so presented. If any fraction of a Warrant Share would, except
for the provisions of this Section 12, be issuable on the exercise of any
Warrants (or specified portion thereof), the Company shall pay an amount
in cash equal to the Exercise Price on the day immediately preceding
the date the Warrant is presented for exercise, multiplied by such
fraction.

SECTION 13. Notices to Warrant Holders. Upon any adjustment
of the Exercise Price pursuant to Section 10, the Company shall promptly
thereafter (i) cause to be filed with the Company a certificate setting
forth the Exercise Price after such adjustment and setting forth in
reasonable detail the method of calculation and the facts upon which such
calculations are based and setting forth the number of Warrant Shares
(or portion thereof) issuable after such adjustment in the Exercise Price,
upon exercise of a Warrant and payment of the adjusted Exercise Price,
which certificate shall be conclusive evidence of the correctness of the
matters set forth therein, and (ii) cause to be given to each of the
registered Holders at his or her address appearing on the Warrant register
written notice of such adjustments by first-class mail, postage prepaid.
Where appropriate, such notice may be given in advance and included as
a part of the notice required to be mailed under the other provisions
of this Section 13.

In case:

<PAGE>

(a) the Company shall authorize the issuance to all holders of
shares of Common Stock of rights, options or warrants to subscribe for or
purchase shares of Common Stock or of any other subscription rights or
warrants; or

(b) the Company shall authorize the distribution to all holders of
shares of Common Stock of evidences of its indebtedness or assets (other
than cash dividends or cash distributions payable out of consolidated
earnings or earned surplus or dividends payable in shares of Common Stock
or distributions referred to in subsection (a) of Section 10 hereof); or

(c) of any consolidation or merger to which the Company is a party
and for which approval of any shareholders of the Company is required, or
of the conveyance or transfer of the properties and assets of the Company
substantially as an entirety, or of any reclassification or change of
Common Stock issuable upon exercise of the Warrants (other than a change
in par value, or from par value to no par value, or from no par value to
par value, or as a result of a subdivision or combination), or a tender
offer or exchange offer for shares of Common Stock; or

(d) of the voluntary or involuntary dissolution, liquidation or
winding up of the Company; or

(e) the Company proposes to take any action (other than actions
of the character described in Section 10(a)) which would require an
adjustment of the Exercise Price or that would require a supplemental
Warrant Agreement pursuant to Section 10;

then the Company shall cause to be given to each of the registered Holders
at his or her address appearing on the Warrant register, at least 20 days
(or 10 days in any case specified in clauses (a) or (b) above) prior to
the applicable record date hereinafter specified, or promptly in the case
of events for which there is no record date, by first class mail, postage
prepaid, a written notice stating (i) the date as of which the holders of
record of shares of Common Stock to be entitled to receive any such rights,
options, warrants or distribution are to be determined, or (ii) the initial
expiration date set forth in any tender offer or exchange offer for shares
of Common Stock, or (iii) the date on which any such consolidation, merger,
conveyance, transfer, dissolution, liquidation or winding up is expected to
become effective or consummated, and the date as of which it is expected
that holders of record of shares of Common Stock shall be entitled to
exchange such shares for securities or other property, if any, deliverable
upon such reclassification, consolidation, merger, conveyance, transfer,

<PAGE>

dissolution, liquidation or winding up. The failure to give the notice
required by this Section 13 or any defect therein shall not affect the
legality or validity of any distribution, right, option, warrant,
consolidation, merger, conveyance, transfer, dissolution, liquidation
or winding up, or the vote upon any action.

Nothing contained in this Agreement or in any of the Warrant
Certificates shall be construed as conferring upon the Holders thereof the
right to vote or to consent or to receive notice as shareholders in
respect of the meetings of shareholders or the election of Directors of
the Company or any other matter, or any rights whatsoever as shareholders
of the Company.

SECTION 14. Registration Rights.

(a) Intentionally omitted.

(b) Demand Registration.

(1) Request for Registration. If Warrants are delivered out
of escrow pursuant to the Bridge Loan Agreement and the Escrow
Agreement, the Holder or Holders of not less than 25% of the
outstanding Registerable Securities may make up to 4 written requests
for registration under the Securities Act ("Demand Registration") of
all or part of its or their Registerable Securities. Notwithstanding
the foregoing, no Demand Registration shall be required to be effected
with respect to any Registerable Securities that are then eligible for
resale pursuant to Rule 144(k) under the Securities Act. Such request
will specify the aggregate amount and type of Registerable Securities
proposed to be sold and will also specify the intended method of
disposition thereof. Within 10 days after receipt of such request, the
Company will give written notice of such registration request to all
other Holders of Registerable Securities and include in such
registration all Registerable Securities with respect to which the
Company has received written requests for inclusion therein from the
Holders thereof within 15 business days after receipt by the applicable
Holder of the Company's notice. Each such request will also specify the
aggregate amount and type of Registerable Securities to be registered
and the intended method of disposition thereof. Unless the Holder or
Holders of a majority of the Registerable Securities to be registered in
such Demand Registration shall consent in writing, no other party,
including the Company (but excluding another Holder of a Registerable

<PAGE>

Security), shall be permitted to offer securities under any such Demand
Registration.

(2) Effective Registration and Expenses. A registration will
not count as a Demand Registration until it has become effective (unless
the majority of the Holders demanding such registration withdraw the
Registerable Securities, in which case such demand will count as a
Demand Registration unless the Holders of such Registerable Securities
agree to pay all Registration Expenses (as hereinafter defined)).
Except as provided above, the Company will pay all Registration Expenses
in connection with any registration initiated as a Demand Registration,
whether or not it becomes effective.

(3) Priority on Demand Registrations. If the Holders of a
majority of the Registerable Securities to be registered in a Demand
Registration so elect the offering of such Registerable Securities
pursuant to such Demand Registration shall be in the form of an
underwritten offering. In such event, if the managing Underwriter or
Underwriters of such offering advise the Company and the Holders in
writing that in their opinion the aggregate amount of Registerable
Securities requested to be included in such offering is sufficiently
large to materially and adversely affect the success of such offering,
the Company will include in such registration the aggregate amount of
Registerable Securities which in the opinion of such managing
Underwriter or Underwriters can be sold without any such material
adverse effect, and such amount shall be allocated pro rata among the
Holders of such issue of Registerable Securities on the basis of the
amount of Registerable Securities requested to be included in such
registration by each such Holder.

(4) Selection of Underwriters. If any Demand Registration is in
the form of an underwritten offering, the Holders of a majority of the
aggregate amount of the Registerable Securities making such demand shall
designate, with the approval of the Company, such approval not to be
unreasonably withheld, the Underwriter or a group of Underwriters to be
utilized in connection with a public offering of the applicable issue of
Registerable Securities.

<PAGE>

(1) If the Company proposes to file a registration statement
under the Securities Act with respect to an offering by the Company for
its own account or for the account of any of its security holders
(provided that, in the case of a registration on demand of such security
holders, the holders of a majority in aggregate principal amount or
number of shares of any such debt securities or equity securities, as
the case may be, consent in writing) of any class of equity security
(other than a registration statement on Form S-4 or S-8 (or any
substitute form that may be adopted by the Securities and Exchange
Commission) or a registration statement in connection with an exchange
offer or offering to the Company's existing security holders or the
issuance of the Exchange Notes pursuant to Section 3.2(e) of the Bridge
Loan Agreement), then the Company shall give written notice of such
proposed filing to the Holders of Registerable Securities as soon as
practicable (but in no event less than ten days before the anticipated
filing date), and such notice shall offer such Holders the opportunity
to register such amount of Registerable Securities as each such Holder
may request (a "Piggy-Back Registration") .

(2) The Company shall use its reasonable best efforts to cause
the managing Underwriter or Underwriters of a proposed underwritten
offering to permit the Registerable Securities requested to be included
in the registration statement for such offering to be included on the
same terms and conditions as any similar securities of the Company or of
such other security holders included therein. Notwithstanding the
foregoing, if the managing Underwriter or Underwriters of such offering
shall have informed the Company in writing that in the opinion of such
Underwriter or Underwriters the success of the offering would be
materially and adversely affected by inclusion of the Registerable
Securities requested to be included because of (i) the kind or
combination of securities which the Holders, the Company and any other
persons or entities intend to include in such offering or (ii) the size
of the offering which the Holders, the Company and such other persons
intend to make, then (a) in the event that the size of the offering is
the basis of such managing Underwriter's opinion, the amount of
securities to be offered for the accounts of Holders and such other
persons (other than the Company) shall be reduced pro rata (based upon
the Registerable Securities and other securities owned by each) to the
extent necessary to reduce the total amount of securities to be included
in such offering to the amount recommended by such managing Underwriter
or Underwriters; and (b) in the event that the kind (or combination) of
securities to be offered is the basis of such managing Underwriter's

<PAGE>

opinion, (x) the Registerable Securities to be included in such offering
shall be reduced as described in clause (a) above or, (y) if the actions
described in clause (x) would, in the judgment of the managing
Underwriter, be insufficient to substantially eliminate the adverse
effect that inclusion of the Registerable Securities and the securities
held by such other persons requested to be included would have on such
offering, such Registerable Securities and other securities will be
excluded from such offering to the extent requested by the managing
Underwriter.

The Company will pay all Registration Expenses (as
hereinafter defined) in connection with each registration of
Registerable Securities.

(d) Registration Procedures.

If and whenever the Company is required to use its best efforts
to effect the registration of any Registerable Securities under the
Securities Act, the Company will promptly:

(1) prepare and file with the Securities and Exchange Commission
a registration statement with respect to such securities and use its
best efforts to cause such registration statement to become effective;

(2) prepare and file with the Securities and Exchange Commission
such amendments and supplements to such registration statement and the
prospectus used in connection therewith as may be necessary to keep such
registration statement effective and to comply with the provisions of
the Securities Act with respect to the disposition of all securities
covered by such registration statement until such time as all of such
securities have been disposed of, but in no event (in the case of Demand
Registration rights) for a period of more than six months after such
registration statement becomes effective;

(3) furnish to counsel (if any) elected by Holders of a majority
(by number of shares) of the Registerable Securities covered by such
registration statement copies of all documents proposed to be filed with
the Securities and Exchange Commission in connection with such
registration, which documents will be subject to the review of such
counsel;

<PAGE>

(4) furnish to each seller of such securities such number of
conformed copies of such registration statement and of each such
amendment and supplement thereto (in each case including all exhibits,
except that the Company shall not be obligated to furnish any seller of
securities with more than two copies of such exhibits), such number of
copies of the prospectus included in such registration statement
(including such preliminary prospectus and any summary prospectus), in
conformity with the requirements of the Securities Act, and such other
documents, as such seller may reasonably request in order to facilitate
the disposition of the securities owned by such seller;

(5) use its best efforts to register or qualify such securities
covered by such registration statement under such other securities or
blue sky laws of such jurisdictions as each seller shall request, and do
any and all other acts and things which may be necessary or advisable to
enable such seller to consummate the disposition in such jurisdictions
of the securities owned by such seller, except that the Company shall
not for any such purpose be required to qualify generally to do business
as a foreign corporation in any jurisdiction wherein it is not so
qualified, or to consent to general service of process in any such
jurisdiction;

(6) furnish to each seller a signed counterpart, addressed to
the sellers of

(i) an opinion of counsel for the Company, dated the
effective date of the registration statement; and

(ii)subject to the accountants obtaining the necessary
representations as specified in Statement on Auditing Standards
No. 72, a "comfort" letter signed by the independent public
accountants who have certified the Company's financial statements
included in the registration statement,

covering substantially the same matters with respect to the registration
statement (and the prospectus included therein) and, in the case of such
accountants' letter, with respect to changes subsequent to the date of
such financial statements, as are customarily covered in opinions of
issuer's counsel and in accountants' letters delivered to the
underwriters in underwritten public offerings of the securities;

<PAGE>

(7) notify each seller of any securities covered by such
registration statement, at any time when a prospectus relating thereto
is required to be delivered under the Securities Act, (i) of the
happening of any event as a result of which the prospectus included
in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state any material fact
required to be stated therein or necessary to make the statements
therein not misleading in light of the circumstances then existing,
or (ii) if the Company is in possession of material information that
it deems advisable not to disclose in a registration statement, and at
the request of any such seller prepare and furnish to such seller a
reasonable number of copies of a supplement to or an amendment of such
prospectus as may be necessary so that, as thereafter delivered to
purchasers of such securities, such prospectus shall not include an
untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements
therein not misleading in light of the circumstances then existing;
provided, however, that upon the occurrence of any event contemplated
by clause (ii) above, the Company shall not be required to prepare
and furnish such supplement or amendment until the earlier of (x) the
date such occurrence ceases or (y) 90 days after notice was first given
under clause (ii), provided, further, that the Company may not delay
preparation and furnishing of such supplement or amendment pursuant
to the preceding proviso on more than two occasions;

(8) otherwise use its best efforts to comply with all applicable
rules and regulations of the Securities and Exchange Commission, and
make available to its security holders, as soon as reasonably
practicable, an earnings statement covering the period of at least
twelve months, but not more than eighteen months, beginning with the
first month after the effective date of the registration statement,
which earnings statement shall satisfy the provisions of Section 11(a)
of the Securities Act; and

(9) use its best efforts to list such securities on AMEX or any
securities exchange on which the Common Stock is then listed, if such
securities are not already so listed and if such listing is then
permitted under the rules of such market exchange, and to provide a
transfer agent and registrar for such Registerable Securities not later
than the effective date of such registration statement.

The Company may require each seller of any securities as to which any
registration is being effected to furnish to the Company such information

<PAGE>

regarding such seller and the distribution of such securities as the
Company may from time to time reasonably request in writing and as shall
be required by law in connection therewith. Each such holder agrees to
furnish promptly to the Company all information required to be disclosed
in order to make the information previously furnished to the Company by
such holder not misleading.

By acquisition of Registerable Securities, each Holder of such
Registerable Securities shall be deemed to have agreed that upon receipt of
any notice from the Company of the happening of any event of the kind
described in Section 14(d)(7) hereof, such Holder will promptly discontinue
such Holder's disposition of Registerable Securities pursuant to the
registration statement covering such Registerable Securities until such
Holder's receipt of the copies of the supplemented or amended prospectus
contemplated by Section 14(d)(7) hereof. If so directed by the Company,
each Holder of Registerable Securities will deliver to the Company (at the
Company's expense) all copies, other than permanent file copies, then in
such Holder's possession of the prospectus covering such Registerable
Securities current at the time of receipt of such notice. In the event
the Company shall give any such notice, the period mentioned in Section
14(d)(2) hereof shall be extended by the number of days during the period
from and including the date of the giving of such notice to and excluding
the date when each seller of any Registerable Securities covered by such
registration statement shall have received the copies of the supplemented
or amended prospectus contemplated by Section 14(d)(7) hereof.

(e) Indemnification.

(1) Indemnification by the Company.

The Company agrees to indemnify and hold harmless each Holder
of Registerable Securities, its officers, directors, employees and agents
and each Person who controls such Holder within the meaning of either
Section 15 of the Securities Act or Section 20(a) of the Exchange Act
(each such person being sometimes hereinafter referred to as an
"Indemnified Holder") from and against all losses, claims, damages,
liabilities and expenses (including reasonable costs of investigation
and legal expenses) arising out of or based upon any untrue statement or
alleged untrue statement of a material fact contained in any registration
statement or prospectus or in any amendment or supplement thereto or in
any preliminary prospectus, or arising out of or based upon any omission
or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, except

<PAGE>

insofar as such losses, claims, damages, liabilities or expenses arise
out of or are based upon any such untrue statement or omission or
allegation thereof based upon information relating to such Indemnified
Holder and furnished in writing to the Company by such Indemnified Holder
expressly for use therein; provided, however, that the foregoing indemnity
agreement with respect to any preliminary prospectus shall not inure to
the benefit of any Holder who failed to deliver a final prospectus
(as then amended or supplemented, provided by the Company to such Holder
in the requisite quantity and on a timely basis to permit proper delivery
on or prior to the relevant transfer of Registerable Securities) to the
Person asserting any losses, claims, damages and liabilities and judgements
caused by any untrue statement or alleged untrue statement of a material
fact contained in any preliminary prospectus, or caused by any omission or
alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, if
such material misstatement or omission or alleged material misstatement
or omission was cured in the final prospectus. This indemnity will be
in addition to any liability which the Company may otherwise have.

If any action or proceeding (including any governmental
investigation or inquiry) shall be brought or asserted against an
Indemnified Holder in respect of which indemnity may be sought from
the Company, such Indemnified Holder shall promptly notify the Company
in writing, and the Company shall assume the defense thereof, including
the employment of counsel satisfactory to such Indemnified Holder and
the payment of all expenses. Such Indemnified Holder shall have the right
to employ separate counsel in any such action and to participate in the
defense thereof, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Holder unless (a) the Company has agreed to
pay such fees and expenses or (b) the Company shall have failed to assume
the defense of such action or proceeding and has failed to employ counsel
satisfactory to such Indemnified Holder in any such action or proceeding
or (c) the named parties to any such action or proceeding (including any
impleaded parties) include both such Indemnified Holder and the Company,
and there are one or more legal defenses available to such Indemnified
Holder which are different from or additional to those available to the
Company (in which case, if such Indemnified Holder notifies the Company
in writing that it elects to employ separate counsel at the expense of
the Company, the Company shall not have the right to assume the defense
of such action or proceeding on behalf of such Indemnified Holder, it
being understood, however, that the Company shall not, in connection
with any one such action or proceeding or separate but substantially
similar or related actions or proceedings in the same jurisdiction arising
out of the same general allegations or circumstances, be liable for the

<PAGE>

reasonable fees and expenses of more than one separate firm of attorneys
at any time for such Indemnified Holder and any other Indemnified Holders,
which firm shall be designated in writing by such Indemnified Holder).
The Company shall not be liable for any settlement of any action or
proceeding effected without its written consent, but if settled with its
written consent, or if there be a final judgment for the plaintiff in
any such action or proceeding, the Company agrees to indemnify and
hold harmless such Indemnified Holders from and against any loss or
liability by reason of such settlement or judgment.

(2) Indemnification by Holder of Registerable Securities.

Each Holder of Registerable Securities severally on behalf of
itself only agrees to indemnify and hold harmless the Company, its
directors and officers and each Person, if any, who controls the Company
within the meaning of either Section 15 of the Securities Act or Section 20
of the Exchange Act to the same extent as the foregoing indemnity from the
Company to such Holder, but only with respect to information relating
to such Holder furnished in writing by such Holder expressly for use in
any registration statement or prospectus, or any amendment or supplement
thereto, or any preliminary prospectus; provided, however, that such
selling Holder shall not be liable in any such case to the extent that
any alleged losses or damages result from the failure of the Company
to promptly amend or take action to correct or supplement any such
registration statement or prospectus on the basis of corrected or
supplemental information provided in writing by such selling Holder
to the Company expressly for such purpose. In case any action or
proceeding shall be brought against the Company or its directors
or officers or any such controlling Person, in respect of which indemnity
may be sought against a Holder of Registerable Securities, such Holder
shall have the rights and duties given to the Company and the Company or
its directors or officers or such controlling Person shall have the rights
and duties given to each Holder by the preceding paragraph. In no
event shall the liability of any Holder of Registerable Securities
hereunder be greater in amount than the dollar amount of the gross
proceeds received by such Holder upon the sale of the Registerable
Securities giving rise to such indemnification obligation.

(3) Contribution.

If the indemnification provided for in this Section 14(e)
is unavailable to an indemnified party under Section 14(e)(1) or
Section 14(e)(2) hereof (other than by reason of exceptions provided
in those Sections) in respect of any losses, claims, damages, liabilities
or expenses referred to therein, then each applicable indemnifying party,

31
<PAGE>

in lieu of indemnifying such indemnified party, shall contribute to the
amount paid or payable by such indemnified party as a result of such
losses, claims, damages, liabilities or expenses in such proportion as
is appropriate to reflect the relative benefits received by the Company
on the one hand and the Holders on the other hand from their sale of
Registerable Securities or if such allocation is not permitted by
applicable law, the relative fault of the Company on the one hand
and of the Indemnified Holder on the other in connection with the
statements or omissions which resulted in such losses, claims, damages,
liabilities or expenses, as well as any other relevant equitable
contributions. The relative fault of the Company on the one hand and
of the Indemnified Holder on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement
of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company or by the
Indemnified Holder and the parties' relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or
omission. The amount paid or payable by a party as a result of the
losses, claims, damages, liabilities and expenses referred to above
shall be deemed to include, subject to the limitations set forth in
the second paragraph of Section 14(e)(1), any legal or other fees or
expenses reasonably incurred by such party in connection with
investigating or defending any action or claim.

The Company and each Holder of Registerable Securities agree
that it would not be just and equitable if contribution pursuant to this
Section 14(e)(3) were determined by pro rata allocation or by any other
method of allocation which does not take account of the equitable
considerations referred to in the immediately preceding paragraph.
Notwithstanding the provisions of this Section 14(e)(3), an Indemnified
Holder shall not be required to contribute any amount in excess of the
amount by which the total price at which the Registerable Securities
sold by such Indemnified Holder or its affiliated Indemnified Holders
and distributed to the public were offered to the public exceeds the
amount of any damages which such Indemnified Holder, or its affiliated
Indemnified Holder, has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.

(f) Certain Definitions.

(1) The term "Holder" shall mean the holder of any Registerable
Security.

<PAGE>

(2) The term "Registerable Securities" shall mean, collectively,
the Warrants, the Warrant Shares and any securities issued or issuable
upon exercise of the Warrants. As to any particular Registerable
Securities, once issued, such securities shall cease to be Registerable
Securities when (A) a registration statement (including a shelf
registration) with respect to the sale of such securities shall have
become effective under the Securities Act and such securities shall
have been disposedof in accordance with such registration statement,
(B) they are eligible for distribution to the public pursuant to the
holding period requirement of Rule 144(k) (or any successor provisions)
under the Securities Act, (C) they shall have been otherwise transferred,
new certificates for them not bearing a legend restricting further
transfer shall have been delivered to the Company and subsequent
disposition of them shall not require registration or qualification of
them under the Securities Act or any similar state law then in force,
or (D) they shall have ceased to be outstanding.

(3) The term "Registration Expenses" shall mean all expenses incident
to the Company's performance of or compliance with Section 14 hereof,
including, without limitation, all registration and filing fees, all
fees and expenses of complying with securities or blue sky laws, fees
and other expenses associated with filings with the NASD (including,
if required, the fees and expenses of any "qualified independent
underwriter" and its counsel), all printing expenses, the fees and
disbursements of counsel for the Company and its independent public
accountants, the fees and disbursements of one counsel retained by
the majority of Holders of Registerable Securities, the expenses of any
special audits made by such accountants required by or incident to such
performance and compliance, but not including (a) fees and disbursements
of more than one counsel retained by the Holders of Registerable
Securities, or (b) such Holders' proportionate share of underwriting
discounts and commissions.

(4) The term "Underwriter" means a securities dealer that purchases
any Registerable Securities as principal and not as part of such dealer's
market-making activities.

SECTION 15. Notices to Company and Warrant Holder. Any notice
or demand authorized by this Agreement to be given or made by the
registered Holder of any Warrant Certificate or on the Company shall be

<PAGE>

sufficiently given or made when and if deposited in the mail, first
class or registered, postage prepaid, addressed to the office of the
Company expressly designated by the Company at its office for purposes
of this Agreement (until the Warrant Holders are otherwise notified
in accordance with this Section by the Company), as follows:

Bio-Rad Laboratories, Inc.
Corporate Offices
1000 Alfred Nobel Drive
Hercules, CA 94547
Attention: General Counsel

Any notice pursuant to this Agreement to be given by the
Company to the registered Holder(s) of any Warrant Certificate shall be
sufficiently given when and if deposited in the mail, first class or
registered, postage prepaid, addressed (until the Company is otherwise
notified in accordance with this Section by such Holder) to such Holder
at the address appearing on the Warrant register of the Company.

SECTION 16. Warrant Agent. (a) The Lenders and the Company
hereby agree that the Company shall serve as warrant agent under this
agreement (the "Warrant Agent"). Upon 30 days' notice to Holders of
Warrants, the Company and the Lenders may appoint a new Warrant Agent.
Such new Warrant Agent shall be a corporation doing business under
the laws of the United States or any state thereof, in good standing and
having a combined capital and surplus of not less than $50,000,000.
The combined capital and surplus of any such new Warrant Agent shall
be deemed to be the combined capital and surplus as set forth in the
most recent annual report of its condition published by such Warrant Agent
prior to its appointment, provided that such reports are published
at least annually pursuant to law or to the requirements of a federal or
state supervising or examining authority. After acceptance in writing
of such appointment by the new Warrant Agent, it shall be vested with
the same powers, rights, duties and responsibilities as if it had been
originally named herein as the Warrant Agent, without any further
assurance, conveyance, act or deed; but if for any reason it shall be
necessary or expedient to execute and deliver any further assurance,
conveyance, act or deed, the same shall be done at the expense of the
Company and shall be legally and validly executed and delivered by the
Company.

(b) Any corporation into which the Company or any new Warrant
Agent may be merged or any corporation resulting from any consolidation
to which the Company or any new Warrant Agent shall be a party or any

<PAGE>

corporation to which the Company transfers substantially all of its
corporate trust or shareholders series business shall be a successor
Warrant Agent under this Agreement without any further act, provided
that such corporation (i) would be eligible for appointment as
successor to the Warrant Agent under the provisions of this Section 16
or (ii) is a wholly owned subsidiary of the Warrant Agent. Any such
successor Warrant Agent shall promptly cause notice of its succession
as Warrant Agent to be mailed (by first class mail, postage prepaid)
to each Holder at such Holder's last address as shown on the register
maintained by the Warrant Agent pursuant to this Agreement.

SECTION 17. Supplements and Amendments. No amendment,
modification, termination or waiver of any term or provision of this
Agreement or of the Warrant Certificates to any departure by the Company
therefrom, shall in any event be effective without the prior written
concurrence of the Company, BOCM, the Agent and the Holders of a majority
in interest of the Warrants.

SECTION 18. Successors. All the covenants and provisions
of this Agreement by or for the benefit of the Company shall bind and
inure to the benefit of its respective successors and assigns hereunder.

SECTION 19. Termination. This Agreement shall terminate at
5:00 p.m., Chicago City time on September 30, 2009.

SECTION 20. Governing Law. THIS AGREEMENT AND EACH WARRANT
CERTIFICATE ISSUED HEREUNDER SHALL BE DEEMED TO BE A CONTRACT MADE UNDER
THE LAWS OF THE STATE OF ILLINOIS AND FOR ALL PURPOSES SHALL BE CONSTRUED
IN ACCORDANCE WITH THE INTERNAL LAWS OF SAID STATE.

SECTION 21. Benefits of This Agreement. Except as specifically
set forth in this Agreement, nothing in this Agreement shall be construed
to give to any person or corporation other than the Company, the Warrant
Agent and the registered Holders of the Warrant Certificates any legal or
equitable right, remedy or claim under this Agreement.

SECTION 22. Counterparts. This Agreement may be executed in
any number of counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall
together constitute but one and the same instrument.

<PAGE>

[Signature Page Follows]

<PAGE>

IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed, as of the day and year first above written.

BIO-RAD LABORATORIES, INC.

By: /s/ Ronald W. Hutton
Name: Ronald W. Huton
Title: Treasurer

BANC ONE CAPITAL MARKETS, INC.,
individually and as Agent

By: /s/ Grant Gieringer
Name: Gran Gieringer
Title: Director

S-1

<PAGE>

EXHIBIT A-1

[Form of Formula Warrant Certificate]

[Face]

NEITHER THE ISSUANCE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE (AND
ANY PREDECESSOR) NOR THE ISSUANCE OF ANY SECURITIES ISSUABLE UPON EXERCISE
HEREOF HAS BEEN REGISTERED UNDER SECTION 5 OF THE UNITED STATES SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO THE
SECURITIES LAWS OF ANY STATE, AND SUCH SECURITIES MAY NOT BE OFFERED,
SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO (i) A REGISTRATION
STATEMENT IN EFFECT WITH RESPECT TO SUCH SECURITIES UNDER THE SECURITIES
ACT AND THE RULES AND REGULATIONS THEREUNDER OR (ii) AN EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE STATE
SECURITIES LAWS.

EXERCISABLE ON OR BEFORE SEPTEMBER 30, 2009

A-1-1

<PAGE>

No. _____

Initial Warrant Certificate

BIO-RAD LABORATORIES, INC.

This Warrant Certificate certifies that Norwest Bank Minnesota,
N.A., as Escrow Agent, or registered assigns, is the registered holder
(collectively, the "Holder") of Warrants evidencing the right to purchase
the "Applicable Number of Shares" of Class A Common Stock, $1.00 par value,
of the Company (the "Common Stock"), as determined in accordance with
Section 12 of the Bridge Loan Agreement dated as of September 30, 1999
among Bio-Rad Laboratories, Inc. (the "Company"), Bank One Capital Markets,
Inc. ("BOCM"), as Agent (the "Agent"), and the lenders party thereto (the
"Lenders") and which have been deposited into escrow pursuant to the terms
of the Escrow Agreement, dated as of September 30, 1999, among the Company,
BOCM, individually and as Agent, and Norwest Bank Minnesota, N.A., as
Escrow Agent, and expiring on September 30, 2009 (the "Warrants").
Each Warrant entitles the holder upon exercise to receive from the Company
on or before 5:00 p.m. Chicago time on September 30, 2009, one fully paid
and nonassessable share of Common Stock (a "Warrant Share") at the
"Applicable Exercise Price" payable in lawful money of the United States
of America upon surrender of this Warrant Certificate, with the form of
election to purchase set forth hereon properly completed and executed,
and payment of the Exercise Price at the office of the Company designated
for such purpose, subject to the conditions set forth herein and in the
Warrant Agreement referred to on the reverse hereof. In lieu of exercising
this Warrant by paying in full the Exercise Price plus transfer taxes
(if applicable pursuant to Section 6 of the Warrant Agreement), if any,
the Warrant holder may, from time to time, convert this Warrant, in whole
or in part, into a number of shares of Common Stock determined by dividing
(a) the aggregate current market price of the number of Shares represented
by the Warrants converted, minus the aggregate Exercise Price for such
shares, plus transfer taxes, if any, by (b) the current market price of
one Share. The current market price shall be determined pursuant to
Section 10(f) of the Warrant Agreement.

"Applicable Exercise Price" means the price equal to 10% over
the last quoted sales price of the Common Stock on AMEX on the Closing
Date.

"Applicable Number of Shares" means shares representing 10% of
the fully-diluted capital stock of the Company.

A-1-2

<PAGE>

The Exercise Price and number of Warrant Shares issuable upon
exercise of the Warrants are subject to adjustment upon the occurrence of
certain events set forth in the Warrant Agreement.

No Warrant may be exercised after 5:00 p.m., Chicago time on
September 30, 2009 and to the extent not exercised by such time such
Warrants shall become void.

Reference is hereby made to the further provisions of this
Warrant Certificate set forth on the reverse hereof and such further
provisions shall for all purposes have the same effect as though fully
set forth at this place.

This Warrant Certificate shall not be valid unless
countersigned by the Company, as such term is used in the Warrant
Agreement.

[Signature Page Follows]

A-1-3

<PAGE>

IN WITNESS WHEREOF, Bio-Rad Laboratories, Inc. has caused this
Warrant Certificate to be signed by its President and by its Secretary.

Dated as of September 30, 1999.

BIO-RAD LABORATORIES, INC.

By:
President

By:
Secretary

A-1-4

<PAGE>

[Form of Warrant Certificate]

[Reverse]

The Warrants evidenced by this Warrant Certificate are part of
a duly authorized issue of Warrants expiring on September 30, 2009,
entitling the holder on exercise to receive shares of Class A Common
Stock, $1.00 par value, of the Company (the "Common Stock"), and are
issued or to be issued pursuant to a Warrant Agreement dated as of
September 30, 1999 (the "Warrant Agreement"), duly executed and
delivered by the Company, which Warrant Agreement is hereby incorporated
by reference in and made a part of this instrument and is hereby referred
to for a description of the rights, limitation of rights, obligations,
duties and immunities thereunder of the Company and the holders (the
words "holders" or "holder" meaning the registered holders or registered
holder) of the Warrants. Capitalized terms used herein shall have the
meanings ascribed in such Warrant Agreement. A copy of the Warrant
Agreement may be obtained by the holder hereof upon written request to the
Company.

Warrants may be exercised at any time on or before September 30,
2009. In the event that upon any exercise of Warrants evidenced hereby the
number of Warrants exercised shall be less than the total number of
Warrants evidenced hereby, there shall be issued to the holder hereof or his
assignee a new Warrant Certificate evidencing the number of Warrants not
exercised. No adjustment shall be made for any dividends on any Common
Stock issuable upon exercise of this Warrant.

The Warrant Agreement provides that upon the occurrence of
certain events the Exercise Price set forth on the face hereof may, subject
to certain conditions, be adjusted. If the Exercise Price is adjusted,
the Warrant Agreement provides that the number of shares of Common Stock
issuable upon the exercise of each Warrant shall be adjusted. No fractions
of a share of Common Stock will be issued upon the exercise of any
Warrant, but the Company will pay the cash value thereof determined as
provided in the Warrant Agreement.

The holders of the Warrants are entitled to certain registration
rights with respect to the Warrants and the Common Stock purchasable upon
exercise thereof. Said registration rights are set forth in Section 14 of
the Warrant Agreement.

A-1-5

<PAGE>

Warrant Certificates, when surrendered at the office of the
Company by the registered holder thereof in person or by its legal
representative or attorney duly authorized in writing, may be exchanged,
in the manner and subject to the limitations provided in the Warrant
Agreement, but without payment of any service charge, for another Warrant
Certificate or Warrant Certificates of like tenor evidencing in the
aggregate a like number of Warrants.

Upon due presentation for registration of transfer of this
Warrant Certificate at the office of the Company a new Warrant Certificate
or Warrant Certificates of like tenor and evidencing in the aggregate a
like number of Warrants shall be issued to the transferee(s) in exchange
for this Warrant Certificate, subject to the limitations provided in the
Warrant Agreement, without charge except for any tax or other governmental
charge imposed in connection therewith.

The Company may deem and treat the registered holder(s) hereof
as the absolute owner(s) of this Warrant Certificate (notwithstanding any
notation of ownership or other writing hereon made by anyone), for the
purpose of any exercise hereof, of any distribution to the holder(s)
hereof, and for all other purposes, and the Company shall not be affected
by any notice to the contrary. Neither the Warrants nor this Warrant
Certificate entitles any holder hereof to any rights of a stockholder of
the Company.

A-1-6

<PAGE>

[Form of Election to Purchase]

(To Be Executed Upon Exercise Of Warrant)

The undersigned hereby irrevocably elects to exercise the
right, represented by this Warrant Certificate, to receive __________
shares of Common Stock and herewith (check item):

(i) tenders payment for such shares to the order of
_________________ in the amount of $_________ in accordance with the
terms hereof; or

(ii) converts this Warrant, in whole or in part, into a
number of shares of Common Stock determined by dividing (a) the aggregate
Current Market Price of the number of shares represented by this Warrant,
minus the aggregate Exercise Price for such shares, plus transfer taxes,
if any, by (b) the Current Market Price of one Share.

The undersigned requests that a certificate for such shares be
registered in the name of ______________, whose address is __________________
and that such shares be delivered to _________________
whose address is _____________________________.

A-1-7

<PAGE>

If said number of shares is less than all of the shares of
Common Stock purchasable hereunder, the undersigned requests that a new
Warrant Certificate representing the remaining balance of such shares be
registered in the name of _____________, whose address is _______________,
and that such Warrant Certificate to be delivered to ___________________,
whose address is _______________________.

Signature:

_______________________________

Date:____________________

Signature Guaranteed:

_______________________________

A-1-8

<PAGE>

EXHIBIT A-2

[Form of Release Warrant Certificate]

[Face]

NEITHER THE ISSUANCE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
(AND ANY PREDECESSOR) NOR THE ISSUANCE OF ANY SECURITIES ISSUABLE UPON
EXERCISE HEREOF HAS BEEN REGISTERED UNDER SECTION 5 OF THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO
THE SECURITIES LAWS OF ANY STATE, AND SUCH SECURITIES MAY NOT BE OFFERED,
SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO (i) A
REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO SUCH SECURITIES UNDER THE
SECURITIES ACT AND THE RULES AND REGULATIONS THEREUNDER OR (ii) AN
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.

EXERCISABLE ON OR BEFORE SEPTEMBER 30, 2009

A-2-1

<PAGE>

No. _____

Release Warrant Certificate

BIO-RAD LABORATORIES, INC.

This Warrant Certificate certifies that ______________________,
or registered assigns, is the registered holder (collectively, the
"Holder") of the number of Warrants determined in accordance with
Section 12 of the Bridge Loan Agreement dated as of September 30, 1999
among Bio-Rad Laboratories, Inc. (the "Company"), Bank One Capital Markets,
Inc. ("BOCM"), First Chicago Capital Corporation, as agent (the
"Agent"), and the lenders party thereto (the "Lenders") and which have
been deposited into escrow pursuant to the terms of the Escrow Agreement,
dated as of September 30, 1999, among the Company, BOCM, the Agent, and
Norwest Bank Minnesota, N.A., as Escrow Agent, and expiring on
September 30, 2009 (the "Warrants") to purchase Class A Common Stock,
$1.00 par value (the "Common Stock"), of the Company. Each Warrant
entitles the holder upon exercise to receive from the Company on or
before 5:00 p.m. Chicago time on September 30, 2009, one fully paid and
nonassessable share of Common Stock (a "Warrant Share") at the "Applicable
Exercise Price" payable in lawful money of the United States of America
upon surrender of this Warrant Certificate, with the form of election to
purchase set forth hereon properly completed and executed, and payment of
the Exercise Price at the office of the Company designated for such
purpose, subject to the conditions set forth herein and in the Warrant
Agreement referred to on the reverse hereof. In lieu of exercising this
Warrant by paying in full the Exercise Price plus transfer taxes (if
applicable pursuant to Section 6 of the Warrant Agreement), if any, the
Warrant holder may, from time to time, convert this Warrant, in whole or
in part, into a number of shares of Common Stock determined by dividing
(a) the aggregate Current Market Price of the number of Shares represented
by the Warrants converted, minus the aggregate Exercise Price for such
shares, plus transfer taxes, if any, by (b) the Current Market Price of
one Share. The Current Market Price shall be determined pursuant to
Section 10(f) of the Warrant Agreement.

The "Applicable Exercise Price" is the price equal to 10% over
the last quoted sales price of the Common Stock on AMEX on the Closing
Date.

A-2-2

<PAGE>

The Exercise Price and number of Warrant Shares issuable upon
exercise of the Warrants are subject to adjustment upon the occurrence
of certain events set forth in the Warrant Agreement.

No Warrant may be exercised after 5:00 p.m., Chicago time on
September 30, 2009 and to the extent not exercised by such time such
Warrants shall become void.

This Warrant Certificate shall not be valid unless
countersigned by the Company, as such term is used in the Warrant
Agreement.

[Signature Page Follows]

A-2-3

<PAGE>

IN WITNESS WHEREOF, Bio-Rad Laboratories, Inc. has
caused this Warrant Certificate to be signed by its President and
by its Secretary.

Dated as of __________________, ____.

BIO-RAD LABORATORIES, INC.

By:
President

By:
Secretary

A-2-4

<PAGE>

[Form of Warrant Certificate]

[Reverse]

The Warrants evidenced by this Warrant Certificate are part of
a duly authorized issue of Warrants expiring on September 30, 2009,
entitling the holder on exercise to receive shares of Class A Common
Stock, $1.00 par value, of the Company (the "Common Stock"), and are
issued or to be issued pursuant to a Warrant Agreement dated as of
September 30, 1999 (the "Warrant Agreement"), duly executed and delivered
by the Company, which Warrant Agreement is hereby incorporated by reference
in and made a part of this instrument and is hereby referred to for a
description of the rights, limitation of rights, obligations, duties and
immunities thereunder of the Company and the holders (the words "holders"
or "holder" meaning the registered holders or registered holder) of the
Warrants. Capitalized terms used herein shall have the meanings ascribed
in such Warrant Agreement. A copy of the Warrant Agreement may be obtained
by the holder hereof upon written request to the Company.

Warrants may be exercised at any time on or before September 30,
2009. In the event that upon any exercise of Warrants evidenced hereby the
number of Warrants exercised shall be less than the total number of
Warrants evidenced hereby, there shall be issued to the holder hereof or
his assignee a new Warrant Certificate evidencing the number of Warrants not
exercised. No adjustment shall be made for any dividends on any Common Stock
issuable upon exercise of this Warrant.

The Warrant Agreement provides that upon the occurrence of
certain events the Exercise Price set forth on the face hereof may,
subject to certain conditions, be adjusted. If the Exercise Price is
adjusted, the Warrant Agreement provides that the number of shares of
Common Stock issuable upon the exercise of each Warrant shall be adjusted.
No fractions of a share of Common Stock will be issued upon the exercise
of any Warrant, but the Company will pay the cash value thereof determined
as provided in the Warrant Agreement.

The holders of the Warrants are entitled to certain
registration rights with respect to the Warrants and the Common Stock
purchasable upon exercise thereof. Said registration rights are set
forth in Section 14 of the Warrant Agreement.

A-2-5

<PAGE>

Warrant Certificates, when surrendered at the office of
the Company by the registered holder thereof in person or by its legal
representative or attorney duly authorized in writing, may be
exchanged, in the manner and subject to the limitations provided in the
Warrant Agreement, but without payment of any service charge, for another
Warrant Certificate or Warrant Certificates of like tenor evidencing
in the aggregate a like number of Warrants.

Upon due presentation for registration of transfer of this
Warrant Certificate at the office of the Company a new Warrant
Certificate or Warrant Certificates of like tenor and evidencing in the
aggregate a like number of Warrants shall be issued to the transferee(s)
in exchange for this Warrant Certificate, subject to the limitations
provided in the Warrant Agreement, without charge except for any tax
or other governmental charge imposed in connection therewith.

The Company may deem and treat the registered holder(s) hereof
as the absolute owner(s) of this Warrant Certificate (notwithstanding
any notation of ownership or other writing hereon made by anyone), for
the purpose of any exercise hereof, of any distribution to the holder(s)
hereof, and for all other purposes, and the Company shall not be affected
by any notice to the contrary. Neither the Warrants nor this Warrant
Certificate entitles any holder hereof to any rights of a stockholder of
the Company.

A-2-6

<PAGE>

[Form of Election to Purchase]

(To Be Executed Upon Exercise Of Warrant)

The undersigned hereby irrevocably elects to exercise the
right, represented by this Warrant Certificate, to receive __________
shares of Common Stock and herewith (check item):

(i) tenders payment for such shares to the order of
_________________ in the amount of $_________ in accordance with
the terms hereof; or

(ii) converts this Warrant, in whole or in part, into
a number of shares of Common Stock determined by dividing (a) the
aggregate Current Market Price of the number of shares represented by
this Warrant, minus the aggregate Exercise Price for such shares, plus
transfer taxes, if any, by (b) the Current Market Price of one Share.

The undersigned requests that a certificate for such shares
be registered in the name of ______________, whose address is
_____________________ and that such shares be delivered to ______________
whose address is _____________________________.

A-2-7

<PAGE>

If said number of shares is less than all of the shares of
Common Stock purchasable hereunder, the undersigned requests that a new
Warrant Certificate representing the remaining balance of such
shares be registered in the name of _____________, whose address
is _______________, and that such Warrant Certificate to be delivered
to ___________________, whose address is _______________________.

Signature:

_______________________________

Date:____________________

Signature Guaranteed:

_______________________________

A-2-8

<PAGE>

EXHIBIT B

Assignment Form

To assign a Warrant Certificate, fill in the form below and the Annex
hereto: (I) or (we) assign and transfer this Warrant Certificate to

(Insert each proposed transferee's soc. sec. or tax I.D. no. and number
of Warrants proposed to be transferred to each such transferee)

_______________________________________________________________________

(Print or type each proposed transferee's name, address and zip code)

_______________________________________________________________________

_______________________________________________________________________
and irrevocably direct any authorized officer of the Company to transfer
such Warrant Certificate(s) on the books of the Company.

________________________________________________________________________

Date: _______________________
_____________________________
_____________________________
_____________________________

Your Signature:___________________

Signature Guaranty.__________________

B-1

<PAGE>

ANNEX TO
ASSIGNMENT FORM

CERTIFICATE TO BE DELIVERED UPON TRANSFER OF WARRANT CERTIFICATES

Re: Warrants issued by Bio-Rad Laboratories, Inc.

This Certificate relates to Warrant Certificate number(s)
__________ held by _______________ (the "Transferor").

The Transferor has requested the Company, by written order,
to register the transfer of such Warrant Certificate(s).

In connection with such request and in respect of each such
Warrant Certificate, the Transferor does hereby certify that the transfer

B-2

<PAGE>

of such Warrant Certificate(s) does not require registration under the
Securities Act (as defined below) because:1

Such Warrants are being acquired for the Transferor's own
account, without transfer.

Such Warrants are being transferred to a "qualified
institutional buyer" (as defined in Rule 144A under the
Securities Act of 1933, as amended (the "Securities Act"))
in reliance on Rule 144A or pursuant to an exemption from
registration in accordance with Rule 904 under the
Securities Act.

Such Warrants are being transferred in accordance with Rule
144 under the Securities Act, or pursuant to an effective
registration statement under the Securities Act.

Such Warrants are being transferred in reliance on and in
compliance with an exemption from the registration
requirements of the Securities Act, other than Rule 144A,
Rule 144 or Rule 904 under the Securities Act. If requested
by the Company, an Opinion of Counsel to the effect that such
transfer does not require registration under the Securities
Act accompanies this Certificate.

(INSERT NAME OF TRANSFEROR)

By:__________________________

Date: ____________________

1 Check applicable box.

B-3

<ARTICLE> 5
<LEGEND> This schedule contains summary financial information extracted
from Bio-Rad Laboratories, Inc. Form 10-Q for the quarter ended
June 30, 1999 and is qualified in its entirety by reference
to such financial statements.
<MULTIPLIER> 1,000

<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-END> SEP-30-1999
<CASH> 11,826
<SECURITIES> 0
<RECEIVABLES> 105,213
<ALLOWANCES> 0
<INVENTORY> 96,385
<CURRENT-ASSETS> 240,351
<PP&E> 205,008
<DEPRECIATION> 120,003
<TOTAL-ASSETS> 376,131
<CURRENT-LIABILITIES> 92,074
<BONDS> 35,367
<COMMON> 12,463
0
0
<OTHER-SE> 221,733
<TOTAL-LIABILITY-AND-EQUITY> 376,131
<SALES> 355,059
<TOTAL-REVENUES> 355,059
<CGS> 158,008
<TOTAL-COSTS> 158,008
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 2,458
<INCOME-PRETAX> 32,123
<INCOME-TAX> 9,187
<INCOME-CONTINUING> 22,936
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 22,936
<EPS-BASIC> 1.89
<EPS-DILUTED> 1.89

</TABLE>